

Objection Deadline: September 23, 2020 @ 12:00 p.m. (ET)

**UNITED STATES BANKRUPTCY COURT
FOR THE SOUTHERN DISTRICT OF NEW YORK**

In re:	Chapter 11
PURDUE PHARMA L.P., <i>et al.</i> , ¹	Case No. 19-23649 (RDD)
Debtors.	(Jointly Administered)

**ELEVENTH MONTHLY FEE STATEMENT OF ALIXPARTNERS, LLP,
FINANCIAL ADVISOR TO THE CHAPTER 11 DEBTORS FOR
ALLOWANCE OF COMPENSATION FOR SERVICES
RENDERED AND FOR REIMBURSEMENT OF EXPENSES
FOR THE PERIOD JULY 1, 2020 THROUGH JULY 31, 2020**

Name of Applicant:	ALIXPARTNERS, LLP	
Applicant’s Role in Case:	Financial Advisor to the Chapter 11 Debtors	
Date Order of Employment Signed:	November 21, 2019 [Docket No. 528], <i>Nunc Pro Tunc</i> to September 15, 2019	
Time period covered by this statement:	Beginning of Period	End of Period
	July 1, 2020	July 31, 2020
Summary of Total Fees and Expenses Requested:		
Total fees requested in this statement:	\$827,644.80 (80% of \$1,034,556.00)	
Total expenses requested in this statement:	\$138.35	
Total fees and expenses requested in this statement:	\$827,783.15	
This is a(n): <u> X </u> Monthly Application ___ Interim Application ___ Final Application		

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY PROFESSIONAL
FOR THE PERIOD JULY 1, 2020 THROUGH JULY 31, 2020**

PROFESSIONAL	TITLE	RATE	HOURS	FEES
Lisa Donahue	Managing Director	\$1,195	49.0	\$ 58,555.00
Richard Collura	Managing Director	\$1,090	40.4	44,036.00
Jesse DelConte	Director	\$950	179.5	170,525.00
Kevin M McCafferty	Director	\$950	204.3	194,085.00
Mark F Rule	Director	\$910	5.5	5,005.00
Michael Hartley	Director	\$840	2.2	1,848.00
Gabe J Koch	Director	\$840	150.1	126,084.00
HS Bhattal	Director	\$840	43.6	36,624.00
Ryan D Sublett	Senior Vice President	\$735	0.4	294.00
Isabel Arana de Uriate	Senior Vice President	\$690	2.2	1,518.00
Sam J Canniff	Senior Vice President	\$645	127.8	82,431.00
Kristina Galbraith	Senior Vice President	\$645	5.6	3,612.00
Fernando O Silva	Senior Vice President	\$645	5.5	3,547.50
Andrew D DePalma	Vice President	\$515	191.3	98,519.50
Sam K Lemack	Vice President	\$515	196.4	101,146.00
Nate A Simon	Vice President	\$515	125.3	64,529.50
Tammy Brewer	Vice President	\$450	9.3	4,185.00
Melanie McCabe	Vice President	\$415	45.9	19,048.50
Mary B Betik	Paraprofessional	\$315	36.4	11,466.00
Barbara J Ferguson	Paraprofessional	\$315	23.8	7,497.00
Total Professional Hours and Fees			1,444.5	\$ 1,034,556.00
Less 50% Travel Fees				-
Subtotal				\$ 1,034,556.00
Less 20% Holdback				(206,911.20)
Invoice Total				\$ 827,644.80
Average Billing Rate				\$ 716.20

ALIXPARTNERS, LLP

**SUMMARY OF HOURS AND FEES BY MATTER CATEGORY
FOR THE PERIOD JULY 1, 2020 THROUGH JULY 31, 2020**

CODE	MATTER CATEGORY	HOURS	FEES
101	Chapter 11 Process/Case Management	140.0	\$ 120,337.50
103	Cash Management	191.2	102,571.00
104	Communication with Interested Parties	139.0	94,252.50
105	U.S. Trustee / Court Reporting Requirements	14.1	8,227.50
106	Business Analysis & Operations	627.8	513,170.50
107	POR Development	3.8	2,337.00
109	Claims Process	59.7	19,239.50
110	Special Projects	56.9	30,727.50
113	Fee Statements and Fee Applications	61.5	29,316.50
114	Court Hearings	3.2	3,040.00
115	Forensic Analysis	147.3	111,336.50
		1,444.5	\$ 1,034,556.00
		Average Billing Rate	\$ 716.20

ALIXPARTNERS, LLP

SUMMARY OF EXPENSES
FOR THE PERIOD JULY 1, 2020 THROUGH JULY 31, 2020

EXPENSE CATEGORY	EXPENSE
Other	\$ 138.35
Total	\$ 138.35

AlixPartners, LLP (“AlixPartners”), as Financial Advisor to the Debtors and its affiliated Debtors, (collectively, the “Debtors”), hereby submits this Eleventh Monthly Fee Statement seeking compensation for professional services rendered and reimbursement of out-of-pocket expenses for the period July 1, 2020 through July 31, 2020 (the “Compensation Period”), pursuant to the *Order Establishing Procedures For Interim Compensation and Reimbursement of Expenses for Retained Professionals* (Docket No. 528) and the *Order Authorizing Debtors to Retain and Employ AlixPartners, LLP as its Financial Advisor Nunc Pro Tunc to the September 16, 2019* [Docket No. 528].

Detailed time descriptions of the services performed by each professional, organized by discrete project and by day is attached hereto as **Exhibit A**. Exhibit A (a) identifies the individuals that rendered services in each subject matter; (b) describes each activity or service that each individual performed; and (c) states the number of hours (in tenths of an hour) spent by each individual providing the services during the Compensation Period.

A detailed analysis of the out-of-pocket expenses showing the amount incurred by each professional in each expense category by day is attached hereto as **Exhibit B**.

WHEREFORE, AlixPartners respectfully requests that it be granted an allowance of compensation for professional services rendered during the Compensation Period in the amount of \$1,034,556.00, without prejudice to a final allowance of compensation, plus reimbursement of actual and necessary out-of-pocket expenses incurred in the amount of \$138.35, and that the Court grant AlixPartners such other and further relief as is just and proper. Pursuant to the Interim Compensation Order, AlixPartners seeks payment of professional fees in the amount of \$827,644.80 (80% of \$1,034,556.00) and expenses in the amount of \$138.35, for a total amount of \$827,783.15.

Dated: September 9, 2020

ALIXPARTNERS, LLP
909 Third Avenue, 28th Floor
New York, NY 10022

/s/ Lisa Donahue

By: Lisa Donahue
Managing Director

Exhibit A

Alix Partners, LLP

Detailed Description of AlixPartners' Fees and Hours by Matter Category

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/01/20	LJD	Update call with J. Dubel (Board Member)	0.50
07/01/20	LJD	Update call with R. Aleali (Purdue).	0.50
07/01/20	LJD	Update call with K. Buckfire (Board Member).	0.50
07/01/20	JD	Review and provide comments on tomorrow's draft weekly call agenda.	0.20
07/01/20	JD	Create draft decision tree for go forward case strategy to be used for board discussion.	1.50
07/01/20	JD	Review and comment on updated case timeline from Davis Polk.	0.30
07/01/20	JD	Correspondence with Davis Polk re: sharing certain materials with various creditor constituencies.	0.40
07/01/20	HSB	Review supporting excel worksheets prepared by S. Lemack (AlixPartners) for cash forecast reports.	2.00
07/01/20	HSB	Review relevant first day motions with relevant background on customer programs and vendors.	0.70
07/02/20	HSB	Review cash report (for week ending 6/26) prepared by S. Lemack (AlixPartners).	0.70
07/02/20	HSB	Review disclosure statements and liquidation analysis for recent pharmaceutical bankruptcies for purpose of preparing Purdue's liquidation analysis.	2.00
07/02/20	HSB	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	JD	Correspondence with J. McClammy (Davis Polk) re: giving LTS access to certain materials.	0.10
07/02/20	JD	Call with J. DelConte, L. Donahue, G. Koch (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (Davis Polk), J.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	
07/02/20	JD	Call with R. Aleali (Purdue) re: follow up from all hands call.	0.30
07/02/20	JD	Call with J. Doyle, R. Aleali (both Purdue), C. Robertson (Davis Polk) re: business development deal.	0.30
07/02/20	JD	Review updated draft pacing calendar and exec summary slide.	0.20
07/02/20	JD	Review draft business development agreement motion.	0.30
07/02/20	JD	Prepare agenda for internal AlixPartners weekly update call.	0.30
07/02/20	JD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie, K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.80
07/02/20	KM	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie, K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.80
07/02/20	ADD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re:	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Weekly update call.	
07/02/20	LJD	Prepare for and attend call with DP and PJT re: board meeting on Friday	0.30
07/02/20	LJD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	LJD	Prepare for and attend call with J. DelConte, L. Donahue, G. Koch (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (Davis Polk), J. O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	1.10
07/02/20	MFR	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	FOS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	SKL	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	SJC	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/02/20	GJK	Call with J. DelConte, L. Donahue, G. Koch (all AlixPartners), M. Kesselman, J. Lowne, R. Aleali (all Purdue), E. Vonnegut, C. Robertson (Davis Polk), J.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		O'Connell, J. Turner, T. Melvin (all PJT) re: case status and go forward planning.	
07/02/20	GJK	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva (all AlixPartners) re: Weekly update call.	0.70
07/03/20	LJD	Update call with PJT.	0.60
07/03/20	LJD	Update call with K. Buckfire (Board Member).	0.80
07/03/20	LJD	Strategy call with DP to discuss POR and next steps.	0.80
07/03/20	JD	Review correspondence re: special committee meetings and scheduling.	0.20
07/06/20	JD	Call with C. Oluwole (Davis Polk) re: diligence uploads.	0.10
07/06/20	JD	Call with L. Donahue, J. DelConte (both AlixPartners), J. O'Connell, T. Coleman, J. Turner (all PJT) re: case progress and go forward planning.	0.40
07/06/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: go forward planning.	0.20
07/06/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update.	0.90
07/06/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence status update.	0.90
07/06/20	LJD	Review communication in advance of special committee call on Tuesday.	0.40
07/06/20	LJD	Update call with K. Buckfire (Board Member).	0.30
07/06/20	LJD	Update call with J. Dubel (Board Member)	0.40
07/06/20	LJD	Prepare for and attend call with L. Donahue, J. DelConte (both AlixPartners), J. O'Connell, T. Coleman, J. Turner (all PJT) re: case progress and go forward planning.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/06/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: go forward planning.	0.20
07/06/20	HSB	Prepare excel summary of disclosure statements and liquidation analysis for recent pharmaceutical bankruptcies for comparative purpose of preparing Purdue's liquidation analysis.	2.80
07/07/20	HSB	Review minimum cash analysis prepared by S. Lemack (AlixPartners) and evaluated minimum cash balance needed (in response to the AHC question on min cash.)	0.60
07/07/20	HSB	Conduct a search for recent pharma bankruptcies and reviewed underlying liquidation analysis.	2.10
07/07/20	HSB	Review AHC diligence question list and the related info on the April Business Plan document.	1.50
07/07/20	LJD	Review AP and PJT comments for special committee meeting.	0.40
07/07/20	LJD	Call with L. Donahue and J. DelConte (both AlixPartners) re: go forward planning discussions.	0.30
07/07/20	LJD	Call with DP re: special committee issues.	0.40
07/07/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence question discussion.	0.20
07/07/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	2.00
07/07/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence question discussion.	0.20
07/07/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue) K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/07/20	JD	Call with L. Donahue and J. DelConte (both AlixPartners) re: go forward planning discussions.	0.30
07/07/20	JD	Correspondence with Davis Polk and PJT re: weekly professionals update call.	0.40
07/07/20	JD	Review and provide comments on ad hoc committee tracker sheet from Davis Polk.	0.50
07/08/20	JD	Call with E. Vonnegut (Davis Polk) re: case status and go forward planning.	0.20
07/08/20	JD	Call with R. Aleali (Purdue) re: open diligence item approvals and case planning.	0.50
07/08/20	JD	Prepare agenda for weekly update call with management, Davis Polk and PJT tomorrow morning.	0.40
07/08/20	JD	Review proposed go forward process from Davis Polk.	0.30
07/08/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Project Catalyst Finance due diligence Questions.	2.00
07/08/20	ADD	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst preparation for diligence call.	0.80
07/08/20	KM	Call A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst preparation for diligence call.	0.80
07/08/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, W. DiNicola (Purdue) re: Project Catalyst Finance due diligence Questions.	2.00
07/08/20	LJD	Review and comment on IAC report.	1.50
07/08/20	LJD	Update call with PJT.	0.40
07/08/20	LJD	Update call with J. Dubel (Board Member).	0.60
07/08/20	HSB	Review weekly sales report prepared by S. Lemack (AlixPartners).	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/08/20	HSB	Review monthly Finance Update report for May 2020 prepared by S. Lemack (AlixPartners).	1.30
07/08/20	HSB	Review monthly Finance Update report (full deck) for May 2020.	0.50
07/09/20	HSB	Review Intralinks data room files (Hypothetical Scenario) while preparing for AHC diligence meeting.	1.10
07/09/20	LJD	Review and discuss board memo re: governance meeting and strategy.	0.60
07/09/20	LJD	Prepare for and attend update call with M. Kesselman (Purdue).	0.50
07/09/20	LJD	Review governance comparison decks and discuss.	1.50
07/09/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst discussion of outstanding diligence items.	1.40
07/09/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) re: Project Catalyst VDR and diligence tracker.	0.70
07/09/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.70
07/09/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst discussion of outstanding diligence items.	1.40
07/10/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence and data room management.	2.40
07/10/20	ADD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		call.	
07/10/20	ADD	Prepare for AlixPartners internal team update call.	0.50
07/10/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence and data room management.	2.40
07/10/20	JD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	KM	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	MFR	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	LJD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	FOS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	SJC	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	SKL	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule,	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	
07/10/20	NAS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	GJK	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	HSB	Review excel file with May cash forecasts for Purdue.	0.50
07/10/20	HSB	Review month of April MOR for Purdue.	0.40
07/10/20	HSB	Review April business plan and compared amounts to actual to date for Purdue.	0.50
07/10/20	HSB	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly update call.	0.60
07/10/20	HSB	Review updated draft of monthly Finance report for May 2020 prepared by S. Lemack (AlixPartners).	0.40
07/13/20	HSB	Review excel file with annual consolidated financial statement forecasts while evaluating minimum cash needs.	0.70
07/14/20	HSB	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut (both Davis Polk) J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners) re: go forward planning and catch up.	1.00
07/14/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), E. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue) re: Project	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Catalyst VDR and diligence tracker.	
07/14/20	GJK	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut (both Davis Polk) J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners) re: go forward planning and catch up.	1.00
07/14/20	LJD	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut (both Davis Polk) J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners) re: go forward planning and catch up.	1.10
07/14/20	LJD	Review and comment on deck discussing confirmation.	0.70
07/14/20	LJD	Review and comment on quarterly fee app.	0.80
07/14/20	JD	Call with C. Robertson (Davis Polk) re: post-call catch up.	0.20
07/14/20	JD	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut (both Davis Polk) J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners) re: go forward planning and catch up.	1.00
07/14/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), E. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue), and K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	1.80
07/15/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update.	0.30
07/15/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update.	0.30
07/16/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Wang (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/16/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst contract diligence process.	0.50
07/16/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst contract diligence process.	0.50
07/16/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), J. Wang (PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola (Purdue), and K. McCarthy (Purdue) re: Project Catalyst VDR and diligence tracker.	1.00
07/16/20	JD	Weekly update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. Lowne, M. Kesselman, R. Aleali (all Purdue) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case status and go forward planning.	0.80
07/16/20	JD	Call with R. Aleali (Purdue) re: group call follow-ups.	0.20
07/16/20	LJD	Weekly update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. Lowne, M. Kesselman, R. Aleali (all Purdue) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case status and go forward planning.	0.80
07/16/20	LJD	Review and comment on UCC deck.	1.10
07/16/20	LJD	Debrief call with PJT.	0.50
07/16/20	GJK	Weekly update call with M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), J. Lowne, M. Kesselman, R. Aleali (all Purdue) J. DelConte, L. Donahue, G. Koch (all AlixPartners) re: case status and go forward planning.	0.80
07/16/20	HSB	Review draft of document with K. Buckfire's (Board Member) questions list and corresponding answers.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/16/20	HSB	Review framework of August business plan document draft prepared by J. Lowne (Purdue).	1.00
07/16/20	HSB	Review Adhansia forecasts and reported results	0.60
07/16/20	HSB	Compare outline of August business plan draft to April version and evaluated additional descriptions based on ytd financial performance.	0.40
07/17/20	HSB	Review list of answers to K. Buckfire's (Board Member) questions.	0.30
07/17/20	HSB	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	HSB	Review sections of the April business plan document for info related to K. Buckfire's (Board Member) questions.	0.30
07/17/20	GJK	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	NAS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	LJD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	LJD	Review UCC / AHC deck and comment.	1.50
07/17/20	MFR	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	FOS	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/17/20	SKL	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	SJC	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	JD	Create agenda for the Purdue weekly update call.	0.30
07/17/20	JD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/17/20	ADD	Prepare for AlixPartners engagement team update call.	0.50
07/17/20	ADD	Call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.50
07/20/20	JD	Review LEK non-reliance letter.	0.20
07/20/20	JD	Correspondence with PJT and management re: process for sharing the distributable value presentation with the individual creditors.	0.40
07/20/20	HSB	Review Customer Program Reports prepared by S. Lemack (AlixPartners).	0.30
07/21/20	HSB	Call with J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetsky (all Davis Polk), G. Koch, HS Bhattal, J. DelConte and L. Donahue (all AlixPartners) re: go forward planning.	0.60
07/21/20	HSB	Review draft of Management's UCC presentation.	1.40
07/21/20	JD	Call with J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetsky (all Davis Polk), G. Koch, HS Bhattal, J. DelConte and L. Donahue (all AlixPartners) re: go forward planning.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/21/20	JD	Call with C. Robertson (Davis Polk) re: open issues.	0.10
07/21/20	JD	Review and comment on chart detailing the positions of the various committees in the case.	0.70
07/21/20	LJD	Prepare for and attend call with J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetsky (all Davis Polk), G. Koch, HS Bhattal, J. DelConte and L. Donahue (all AlixPartners) re: go forward planning.	0.70
07/22/20	JD	Call with M. Kesselman (Purdue), J. O'Connell, J. Turner (both PJT) re: case update.	0.60
07/22/20	HSB	Review updated draft of responses to K. Buckfire (Board Member) questions.	0.30
07/22/20	HSB	Review weekly sales report (week ending 07/17) prepared by S. Lemack (AlixPartners).	0.30
07/24/20	HSB	Review disclosure statements and related liquidation analysis for recent pharma bankruptcies.	1.00
07/24/20	HSB	Review updated draft of responses to Purdue Board's strategic questions.	0.30
07/24/20	HSB	Continue to review disclosure statements & liquidation analysis for recent pharma bankruptcies.	0.40
07/24/20	HSB	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	JD	Prepare agenda for AlixPartners weekly update call.	0.30
07/24/20	JD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	ADD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		(all AlixPartners) re: Weekly team update call.	
07/24/20	ADD	Prepare for AlixPartners internal Purdue engagement team update meeting.	0.30
07/24/20	LJD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	MFR	Prepare for and attend call with HS Bhattal, S. Canniff, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, and N. Simon (all AlixPartners) re: Weekly Update call.	0.60
07/24/20	FOS	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	SKL	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	NAS	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/24/20	GJK	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, F. Silva, M. Rule, N. Simon (all AlixPartners) re: Weekly team update call.	0.60
07/26/20	LJD	Prepare for and attend preparation call for UCC meeting tomorrow with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut (both Davis Polk), J. DelConte, and L. Donahue (both AlixPartners).	1.80
07/26/20	JD	Prep call for UCC call tomorrow with M. Kesselman, C. Landau, J. Lowne, R. Aleali (all Purdue), J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut (both Davis	1.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		Polk), J. DelConte, and L. Donahue (both AlixPartners).	
07/27/20	HSB	Review final draft of document with responses to strategic questions raised by the Purdue Board.	0.30
07/28/20	HSB	Review weekly cash flow model file prepared by S. Lemack (AlixPartners).	0.80
07/28/20	HSB	Review investments file prepared by S. Lemack (AlixPartners).	0.50
07/28/20	NAS	Diligence call with D. Jefferies (Mundipharma Treasurer), G. Koch (AlixPartners), and other Mundipharma diligence advisors.	1.10
07/28/20	GJK	Diligence call with D. Jefferies (Mundipharma Treasurer), N. Simon (AlixPartners), and other Mundipharma diligence advisors.	1.10
07/29/20	HSB	Review OCP report prepared by S. Lemack (AlixPartners).	0.30
07/29/20	HSB	Review disclosure statements for recent pharma bankruptcies.	0.60
07/30/20	GJK	Mundipharma diligence call with S. Jamieson (Management Revisions), N. Simon (AlixPartners), and other Mundipharma diligence advisors.	1.80
07/30/20	GJK	Discussion with N. Simon (AlixPartners), FTI, and Province re: current status of Mundipharma diligence process and post-call debrief with N. Simon (AlixPartners).	0.80
07/30/20	NAS	Mundipharma diligence call with S. Jamieson (Management Revisions), G. Koch (AlixPartners), and other Mundipharma diligence advisors.	1.80
07/30/20	NAS	Discussion with G. Koch (AlixPartners), FTI, and Province re: current status of Mundipharma diligence process and post-call debrief with G. Koch (AlixPartners).	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
07/31/20	GJK	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	GJK	Provide Mundipharma update on weekly AlixPartners team coordinating call.	0.50
07/31/20	JD	Prepare agenda for Alix weekly update call.	0.30
07/31/20	JD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	LJD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	MFR	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	MFR	Calls with F. Silva (AlixPartners) re: UCC Information requests.	0.30
07/31/20	SKL	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	FOS	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	FOS	Calls with M. Rule (AlixPartners) re: UCC Information	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Date	Consultant	Description of Services	Hours
		requests.	
07/31/20	NAS	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	KM	Call with R. Schnitzler (PJT), A. DePalma (AlixPartners) and J. Lieberman (SK Capital) re: interested party diligence update.	0.60
07/31/20	KM	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	ADD	Call with R. Schnitzler (PJT), K. McCafferty (AlixPartners) and J. Lieberman (SK Capital) re: Interested party diligence update.	0.60
07/31/20	ADD	Prepare for AlixPartners internal Purdue engagement team update meeting.	0.40
07/31/20	ADD	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
07/31/20	HSB	Call with HS Bhattal, J. DelConte, A. DePalma, L. Donahue, G. Koch, S. Lemack, K. McCafferty, M. Rule, F. Silva, N. Simon (all AlixPartners) re: Weekly team update call.	0.50
Total			140.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Chapter 11 Process/Case Management
Client/Matter # 012589.00101

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	20.00	515.00	10,300.00
Sam K Lemack	2.90	515.00	1,493.50
Nate A Simon	5.90	515.00	3,038.50
Fernando O Silva	3.20	645.00	2,064.00
Sam J Canniff	1.80	645.00	1,161.00
HS Bhattal	32.20	840.00	27,048.00
Gabe J Koch	9.90	840.00	8,316.00
Mark F Rule	3.20	910.00	2,912.00
Jesse DelConte	18.60	950.00	17,670.00
Kevin M McCafferty	17.20	950.00	16,340.00
Lisa Donahue	25.10	1,195.00	29,994.50
Total Hours & Fees	140.00		120,337.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/01/20	HSB	Meeting with HS Bhattal and S. Lemack (both AlixPartners) to discuss cash reporting process and procedures.	0.90
07/01/20	SKL	Meeting with HS Bhattal and S. Lemack (both AlixPartners) to discuss cash reporting process and procedures.	0.90
07/01/20	SKL	Prepare the Purdue and Rhodes IAC summaries and prepared updated to the deck accordingly.	1.50
07/01/20	SKL	Finalize updates to the Purdue and Rhodes cash summaries and prepared list of open items.	1.40
07/01/20	SKL	Review the latest EastWest cash transaction report and categorized for the week ended 06/26 cash report.	2.00
07/01/20	SKL	Review the latest Paysource cash transaction report and categorized for the week ended 06/26 cash report.	1.60
07/01/20	SKL	Create accounts payable release file.	0.80
07/02/20	SKL	Create accounts payable release file.	0.80
07/02/20	SKL	Prepare and finalize updates to the weekly cash report deck and circulated for final sign-off.	1.90
07/02/20	SKL	Review updates provided by E. Nowakowski (Purdue) and J. Liceaga (TXP) and finalized updates to the Purdue and Rhodes cash summaries accordingly.	1.40
07/02/20	SKL	Update the latest Purdue forecast with this past week's cash actuals and prepared the Purdue forecast to actual analysis.	1.90
07/02/20	SKL	Update the latest Rhodes forecast with this past week's cash actuals and prepared the Rhodes forecast to actual analysis.	1.50
07/02/20	JD	Correspondence with HS Bhattal and S. Lemack (both AlixPartners) re: last 2 weekly forecast to actual cash	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		reports with review of the latest reports.	
07/06/20	SKL	Create accounts payable release file.	0.90
07/06/20	SKL	Prepare the latest Monthly Flash reports and provided to R. Aleali (Purdue) per her request.	0.40
07/06/20	SKL	Finalize the Purdue and Rhodes Medicaid piece of the March Customer Programs report.	2.10
07/06/20	SKL	Finalize the Purdue and Rhodes Commercial rebate piece of the March Customer Programs report.	2.70
07/06/20	SKL	Prepare breakdown of June prepetition payments per J. Lowne (Purdue) request.	0.80
07/06/20	SKL	Update the Medicaid by state breakout for the Customer Programs report.	1.30
07/06/20	SKL	Finalize updates to the rebate summary section of the March Customer Programs report and circulated for final sign-off.	1.90
07/07/20	SKL	Prepare operational disbursements through 2020 and began preparing the updated analysis re: min cash balance.	2.30
07/07/20	SKL	Finalize updates to the Medicaid piece of the March Customer Programs report based on the feedback provided by E. Nowakowski (Purdue) and circulated for final sign-off.	1.80
07/07/20	SKL	Prepare analysis of the latest retained professional payments and circulated inquiry to H. Benson (TXP) to help provide additional info.	0.70
07/07/20	SKL	Finalize updates to the week ended 06/26 cash report and circulated to the DPW team to begin the production process.	1.30
07/07/20	SKL	Finalize updates to the Min. Cash Analysis based on the feedback provided by J. DelConte (AlixPartners) and	2.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		circulated update to the AlixPartners team.	
07/07/20	SKL	Create accounts payable release file.	0.80
07/08/20	SKL	Create accounts payable release file.	0.70
07/09/20	SKL	Create accounts payable release file.	0.90
07/09/20	SKL	Call with HS Bhattal, S. Lemack and J. DelConte (all AlixPartners) re: minimum cash balance analysis.	0.50
07/09/20	SKL	Review the latest EastWest cash transaction report and categorized for the week ended 07/03 cash report.	2.00
07/09/20	SKL	Review the latest Paysource cash transaction report and categorized for the week ended 07/03 cash report.	1.90
07/09/20	SKL	Review and reconcile the latest investment activity files provided by J. Liceaga (TXP) and updated the investment section of the week ended 07/03 weekly cash report accordingly.	1.30
07/09/20	SKL	Review and reconcile the latest IAC cash activity provided by J. Liceaga (TXP) and circulated list of open-items to E. Nowakowski (Purdue).	1.40
07/09/20	JD	Review latest cash flow forecasts, cash actual reporting and business plan cash forecasts to respond to outstanding questions from the AHC on year end cash forecast.	1.20
07/09/20	JD	Call with HS Bhattal, S. Lemack and J. DelConte (all AlixPartners) re: minimum cash balance analysis.	0.50
07/09/20	HSB	Call with HS Bhattal, S. Lemack and J. DelConte (all AlixPartners) re: minimum cash balance analysis.	0.50
07/10/20	SKL	Create accounts payable release file.	0.80
07/10/20	SKL	Finalize reconciliation of the IAC feedback provided by J. Liceaga (TXP) and R. Brown (Purdue) and updated the weekly cash report accordingly.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/10/20	SKL	Update the latest Rhodes forecast with this past week's cash actuals and prepared the Rhodes forecast to actual analysis.	1.60
07/10/20	SKL	Update the latest Purdue forecast with this past week's cash actuals and prepared the Purdue forecast to actual analysis.	1.60
07/13/20	SKL	Review the latest Purdue investment activity and prepared the updated Purdue account balances for the June Monthly Operating Report.	2.20
07/13/20	SKL	Review and reconcile the latest feedback provided by J. Liceaga (TXP) and R. Brown (Purdue) re: week ended 07/03 cash report and updated the report accordingly.	2.30
07/13/20	SKL	Finalize updates to the week ended 07/03 weekly cash report deck and circulated internally for final sign-off.	1.90
07/13/20	SKL	Review latest batch of Indemnatee invoices provided by C. MacDonald (Purdue) and included in today's AP release files.	0.50
07/13/20	SKL	Create accounts payable release file.	0.80
07/13/20	SKL	Finalize updates to the May PEO Flash report and sent to Chris Robertson (Davis Polk) to begin the production process.	0.50
07/13/20	JD	Review and provide comments on the latest cash report.	0.50
07/13/20	HSB	Review underlying excel document for the weekly cash report.	0.20
07/13/20	HSB	Review weekly cash actuals report for the week of 7/03 prepared by S. Lemack (AlixPartners).	0.80
07/14/20	JD	Review minimum cash analysis put together by S. Lemack (AlixPartners).	0.50
07/14/20	SKL	Create accounts payable release file.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/14/20	SKL	Continue to finalize updates to the Min. Cash Analysis based on the inquiry from FTI.	1.80
07/14/20	SKL	Review and reconcile professional payments made in June and prepared the professional payment section of the Monthly Operating Report accordingly.	2.10
07/14/20	SKL	Finalize review of the cash receipts and disbursements from the month of June and prepared the updated cash activity section the Monthly Operating Report.	2.60
07/15/20	SKL	Review updates provided by C. Ostrowski (Purdue) re: Customer Programs and finalized updates to the report.	1.80
07/15/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 07/10 cash report.	2.10
07/15/20	SKL	Create accounts payable release file.	0.70
07/15/20	SKL	Review the latest PaySource cash transaction report and categorized for the week ended 07/10 cash report.	1.80
07/15/20	SKL	Review and reconcile the latest IAC transactions, prepared the updated IAC summaries and prepared list of open IAC inquiries for J. Liceaga (TXP) and E. Nowakowski (Purdue) to review.	1.50
07/15/20	SKL	Review and reconcile the latest Purdue investment activity and updated the weekly cash report accordingly.	0.90
07/15/20	HSB	Review underlying excel file with financial statements for May reporting.	1.20
07/15/20	HSB	Analyze actual ytd financial results per the May flash report and compared against business plan forecasts.	0.60
07/16/20	SKL	Review and reconcile the latest Rhodes Medicaid and Commercial rebate info provided by the Rhodes Pharma team and updated the April Customer Programs report accordingly.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/16/20	SKL	Review and reconcile the latest Purdue Medicaid and Commercial rebate info provided by the E. Nowakowski (Purdue) and updated the April Customer Programs report accordingly.	2.20
07/16/20	SKL	Finalize updates to the remaining sections of the April Customer Programs report, Customer Programs deck, and circulated update to C. Ostrowski (Purdue) for final sign-off.	2.60
07/16/20	SKL	Review the latest feedback provided by C. Ostrowski (Purdue) re: April's Customer Programs report, updated the report accordingly, and began preparing a redacted version of the final deck.	1.60
07/16/20	SKL	Create accounts payable release file.	0.80
07/17/20	SKL	Create accounts payable release file.	1.10
07/17/20	SKL	Finalize review of the latest weekly cash report feedback provided by J. Liceaga (TXP) and R. Brown (Purdue) and updated the Purdue and Rhodes cash summaries accordingly.	1.30
07/17/20	SKL	Prepare the updated Purdue forecast-to-actuals section of the weekly cash report and prepared and finalized the Purdue slides of the report.	1.30
07/17/20	SKL	Prepare the updated Rhodes forecast-to-actuals section of the weekly cash report and prepared and finalized the Rhodes slides of the report.	1.30
07/17/20	SKL	Finalize Min. Cash Analysis and prepared updated response to the AHC open question list.	0.80
07/17/20	SKL	Review and reconcile prepetition invoices paid in June and prepared updated analysis for J. Lowne (Purdue) review.	0.60
07/17/20	SKL	Review the docket for the latest fee applications filed by Restructuring and Retained Professionals to updated our	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		professional tracker accordingly.	
07/17/20	JD	Review and provide comments on the latest cash forecast to actual.	0.50
07/17/20	HSB	Review weekly cash report prepared by S. Lemack (AlixPartners).	0.70
07/20/20	HSB	Review updated weekly cash report (week ended 7/10) prepared by S. Lemack (AlixPartners).	0.20
07/20/20	JD	Review and provide comments on latest draft forecast to actual cash report.	0.60
07/20/20	SKL	Create accounts payable release file.	1.00
07/20/20	SKL	Finalize remaining updates to the week ended 07/10 cash report and circulated for final sign-off.	0.80
07/20/20	SKL	Review the latest OCP payment inquiry and prepared updated OCP breakdown.	1.30
07/20/20	SKL	Finalize remaining updates to the March and April Customer Program's reports and circulated for final sign-off.	2.10
07/20/20	SKL	Prepare for and participate in OCP discussion with C. MacDonald (Purdue).	0.50
07/20/20	SKL	Begin reconciliation of the latest fee applications filed by retained professionals re: 13-week forecast.	1.40
07/20/20	SKL	Continue reconciliation of the latest fee applications filed by restructuring professionals re: 13-week forecast.	2.00
07/21/20	SKL	Refresh the week ended 07/10 cash report with the latest IAC feedback provided by J. Liceaga (TXP) and recirculated final version of the deck.	1.50
07/21/20	SKL	Review latest feedback and reconciliation of customer deposits re: 13-week cash forecast.	0.50
07/21/20	SKL	Review the latest EastWest cash transaction report	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
		provided by J. Liceaga (TXP) and categorized for the week ended 07/17 cash report.	
07/21/20	SKL	Review the latest Paysource transaction report and categorized for the week ended 07/17 cash report.	1.80
07/21/20	SKL	Review and reconcile the latest Purdue rebate tracker provided by D. Krishnan (Purdue) and updated the week ended 07/17 cash report accordingly.	1.30
07/21/20	SKL	Review and reconcile the latest IAC transactions for Purdue and Rhodes and prepared the updated IAC summaries for the week ended 07/17 cash report accordingly.	1.20
07/21/20	SKL	Create accounts payable release file.	0.80
07/22/20	SKL	Create accounts payable release file.	0.80
07/22/20	SKL	Finalize updates to the Purdue section of the week ended 07/17 cash report, prepared the forecast-to-actuals analysis and updated the cash report accordingly.	1.60
07/22/20	SKL	Finalize updates to the Rhodes section of the week ended 07/17 cash report, prepared the forecast-to-actuals analysis and updated the cash report accordingly.	1.30
07/22/20	SKL	Review and reconcile the latest Purdue weekly sales info provided by E. Nowakowski (Purdue) and prepared the updated Purdue weekly sales report accordingly.	1.20
07/22/20	SKL	Review and reconcile the latest Rhodes weekly sales info provided by P. Phouthasone (Rhodes) and prepared the updated Rhodes weekly sales report accordingly.	1.00
07/22/20	SKL	Review and reconcile non-recurring legal fees based on the May 2020 financials provided by the company.	2.10
07/22/20	SKL	Begin preparing updated Liquidation Analysis based on May financials.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/22/20	SKL	Prepare for Liquidation analysis meeting.	0.60
07/22/20	JD	Review and provide comments on latest cash forecast to actual report.	0.30
07/22/20	HSB	Review weekly cash report (week ending 07/17) prepared by S. Lemack (AlixPartners).	0.40
07/23/20	SKL	Finalize updates to the week ended 07/17 weekly cash report based on the feedback provided by J. Liceaga (TXP) and circulated for final sign-off.	1.40
07/23/20	SKL	Finalize review and reconciliation of non-recurring legal fees.	1.40
07/23/20	SKL	Continue to finalize review and reconciliation of the latest fee applications filed by retained professionals re: 13-week forecast.	2.30
07/23/20	SKL	Continue to finalize review and reconciliation of the latest fee applications filed by restructuring professionals re: 13-week forecast.	2.20
07/23/20	SKL	Create accounts payable release file.	1.20
07/24/20	SKL	Create accounts payable release file.	0.80
07/24/20	SKL	Continue to create a refreshed liquidation analysis based on May financials, and began reviewing the underlying assumptions for the high, mid and low case.	2.70
07/24/20	SKL	Finalize review of the restructuring professional fee applications, updated the restructuring professional tracker, and circulated list of open inquiries to C. MacDonald (Purdue).	1.80
07/24/20	SKL	Finalize review of the retained professional fee applications, update the retained professional tracker, and circulate list of open inquiries to C. MacDonald (Purdue).	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/24/20	SKL	Begin updating the latest Purdue 13-week forecast summary and bringing in the latest A/P and A/R source information.	1.80
07/27/20	SKL	Create accounts payable release file.	0.70
07/27/20	SKL	Review and reconcile the latest receipt forecast and update the Purdue cash forecast accordingly.	2.40
07/27/20	SKL	Pull the latest Purdue A/R detail from SAP and begin updating the receipt section of the Purdue forecast accordingly.	1.50
07/27/20	SKL	Pull the latest Purdue A/P detail from SAP and begin updating the operating expense section of the Purdue forecast accordingly.	1.80
07/27/20	SKL	Review and reconcile the latest Purdue customer rebate forecast and update the Purdue cash forecast accordingly.	2.60
07/28/20	SKL	Finalize review and reconciliation of latest retained professional fee applications filed and update the Purdue cash forecast accordingly.	1.80
07/28/20	SKL	Finalize review and reconciliation of latest restructuring professional fee applications filed and update the Purdue cash forecast accordingly.	1.80
07/28/20	SKL	Review the latest EastWest cash transaction report provided by J. Liceaga (TXP) and categorized for the week ended 07/24 cash report.	1.80
07/28/20	SKL	Review the latest Paysource transaction report and Integrated Payables report and categorized for the week ended 07/24 cash report.	2.40
07/28/20	SKL	Review and reconcile latest finance report slides from C. George (Purdue) and redact and recirculate deck to begin the production process.	1.10
07/28/20	SKL	Create accounts payable release file.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/29/20	SKL	Create accounts payable release file.	0.80
07/29/20	SKL	Prepare for and participate in discussions with C. MacDonald (Purdue) re: OCP fees/expenses incurred.	1.10
07/29/20	SKL	Review and reconcile latest OCP fee/expense detailed provided by C. MacDonald (Purdue) and updated the OCP report accordingly.	1.60
07/29/20	SKL	Prepare final list of updates for the June OCP report and circulated final report for DPW review.	2.10
07/29/20	SKL	Review and reconcile the latest IAC transactions for Purdue and Rhodes and prepared the updated IAC summaries for the week ended 07/24 cash report accordingly.	1.10
07/29/20	SKL	Review latest feedback provided re: Rhodes customer rebates and update the Rhodes cash forecast accordingly.	2.60
07/30/20	SKL	Create accounts payable release file.	0.60
07/30/20	SKL	Pull the latest Rhodes A/P detail from SAP and begin updating the operating expense section of the Rhodes forecast accordingly.	1.30
07/30/20	SKL	Pull the latest Purdue A/R detail from SAP and begin updating the receipt section of the Purdue forecast accordingly.	1.20
07/30/20	SKL	Finalize updates to the customer receipt section of the Rhodes cash forecast.	2.10
07/30/20	SKL	Finalize updates to the operating expense section of the Rhodes cash forecast.	2.40
07/30/20	SKL	Finalize updates to the IAC receipts section of the Rhodes cash forecast.	1.70
07/31/20	SKL	Finalize updates to the IAC disbursements section of the Rhodes cash forecast.	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Date	Consultant	Description of Services	Hours
07/31/20	SKL	Prepare updated Rhodes forecast-to-actual slides for the week ended 07/24 cash forecast.	0.60
07/31/20	SKL	Prepare updated Purdue forecast-to-actual slides for the week ended 07/24 cash forecast.	0.60
07/31/20	SKL	Finalize updates to the Purdue cash forecast and update the Purdue slides of the latest cash forecast deck accordingly.	2.40
07/31/20	SKL	Finalize updates to the Rhodes cash forecast and update the Rhodes slides of the latest cash forecast deck accordingly.	2.10
07/31/20	SKL	Update the cash forecast with the latest feedback provided and recirculate for final sign-off.	0.70
07/31/20	SKL	Create accounts payable release file.	0.90
07/31/20	HSB	Review Cash Forecast report prepared by S. Lemack (AlixPartners).	0.70
Total			191.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Cash Management
Client/Matter # 012589.00103

Fee Recap:

Consultant	Hours	Rate	Amount
Sam K Lemack	180.20	515.00	92,803.00
HS Bhattal	6.20	840.00	5,208.00
Jesse DelConte	4.80	950.00	4,560.00
Total Hours & Fees	191.20		102,571.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
07/01/20	ADD	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with interested party.	0.80
07/01/20	ADD	Call with J. DelConte, A. DePalma and K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with a second interested party.	1.50
07/01/20	JD	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with interested party.	0.80
07/01/20	JD	Partial participation in call with J. DelConte, A. DePalma and K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with a second interested party.	1.30
07/01/20	JD	Call with W. Curran, C. Robertson, C. Oluwole (all Davis Polk), T. Melvin, J. Turner (both PJT), M. Florence, J. Bragg (both Skadden), J. Bucholtz (both King & Spalding), R. Aleali, M. Kesselman (both Purdue) re: pre-call for Duff & Phelps call.	0.40
07/01/20	BJF	Research third party confidentiality for due diligence request.	1.80
07/01/20	JD	Correspondence with J. Doyle, R. Aleali (both Purdue) and C. Robertson (Davis Polk) re: Prodrug diligence items.	0.30
07/01/20	JD	Review management comments on non-PEO April flash report.	0.20
07/01/20	JD	Correspondence with PJT and management re: Project Catalyst diligence responses.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
07/01/20	JD	Edit UCC diligence responses and collect and edit various responsive excel files to share. Circulate documents to internal group for approval prior to moving to get processed and uploaded.	1.70
07/01/20	KM	Call with J. DelConte, A. DePalma and K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with a second interested party.	1.50
07/01/20	KM	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), R. Schnitzler (PJT), D. Fogel, R. Shamblen, J. Doyle, D. Lundie (Purdue) K. McCarthy (Purdue) re: Project Catalyst interview with interested party.	0.80
07/01/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update and compilation of diligence responses, and upload materials to the VDR.	2.00
07/02/20	ADD	Prepare and organize files provide by Davis Polk eDiscovery team for upload to the data room.	2.80
07/02/20	ADD	Upload files provided by David Polk eDiscovery team to the data room.	1.30
07/02/20	JD	Review UCC motion for additional discovery and examinations.	0.40
07/02/20	JD	Review response to draft UCC diligence responses and correspondence with production team to push to process documents and response.	0.50
07/02/20	JD	Provide final responses to open business development diligence questions.	0.30
07/05/20	JD	Correspondence with Province re: status of open diligence items.	0.30
07/05/20	JD	Correspondence with R. Collura and A. DePalma (both	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		AlixPartners) re: Province diligence question on the chart of accounts.	
07/05/20	JD	Review correspondence from A. DePalma (AlixPartners) and C. Oluwole (Davis Polk) re: AHC questions on sharing materials.	0.30
07/06/20	JD	Call with R. Aleali (Purdue) re: outstanding UCC diligence request items.	0.40
07/06/20	JD	Correspondence with Purdue and Dechert teams re: monitor requests.	0.50
07/06/20	JD	Review AHC diligence questions and proposed responses.	0.30
07/06/20	ADD	Compile and format materials submitted in response to diligence requests for approval, processing and production.	1.90
07/07/20	ADD	Review and redact third-party information from board materials submitted in response to diligence requests in preparation for production.	2.20
07/07/20	SJC	Review and redact board meeting minutes in preparation for processing an upload to data room.	3.00
07/07/20	SJC	Continue to review and redact board meeting minutes in preparation for processing an upload to data room.	1.00
07/08/20	SJC	Review and redact Rhodes' board meeting minutes in preparation for processing an upload to data room.	4.00
07/08/20	ADD	Review and redact third-party information from board materials (Rhodes entities) submitted in response to diligence requests in preparation for production.	2.70
07/08/20	KM	Call with R. Schnitzler (PJT), interested party diligence team re: environmental response process overview.	0.50
07/08/20	JD	Call with M. Diaz, B. Bromberg (both FTI), G. Coutts, H. Schenk (both Houlihan), J. Turner, R. Schnitzler (both PJT), J. Lowne, M. Ronning, D. Rosen (all Purdue) re:	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		delayed bankruptcy emergence scenario.	
07/08/20	JD	Correspondence with J. Lowne (Purdue) and PJT re: OxyContin only scenario request from the UCC and AHC.	0.60
07/08/20	JD	Review final financial tables to be uploaded per UCC request.	0.20
07/08/20	JD	Edit final business development diligence materials and send around to the internal group for final approval.	0.50
07/09/20	JD	Attend AHC diligence questions meeting with B. Bromberg, C. Kim, M. Diaz (all FTI), J. Turner, T. Melvin (both PJT), J. DelConte, S. Lemack, and HS Bhattal (all AlixPartners).	0.70
07/09/20	JD	Review Project Catalyst proposed diligence response from D. Fogel (Purdue).	0.30
07/09/20	ADD	Review and redact third-party information from files submitted in response to diligence requests in preparation for production.	1.90
07/09/20	SJC	Review and redact Rhodes' board meeting minutes in preparation for processing an upload to data room.	3.00
07/09/20	SKL	Attend AHC diligence questions meeting with B. Bromberg, C. Kim, M. Diaz (all FTI), J. Turner, T. Melvin (both PJT), J. DelConte, S. Lemack, and HS Bhattal (all AlixPartners).	0.70
07/09/20	HSB	Attend AHC diligence questions meeting with B. Bromberg, C. Kim, M. Diaz (all FTI), J. Turner, T. Melvin (both PJT), J. DelConte, S. Lemack, and HS Bhattal (all AlixPartners).	0.70
07/10/20	SJC	Review and redact Rhodes board materials from the P drive in preparation for processing an upload to data room.	2.50
07/13/20	SJC	Review and redact board meeting minutes in preparation	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		for processing an upload to data room.	
07/13/20	ADD	Compile and upload files provided in response to diligence request for processing and upload to the data room.	1.60
07/13/20	JD	Correspondence with management re: FTI diligence request on IMS data.	0.30
07/13/20	JD	Call with J. Turner, R. Schnitzler, T. Melvin (all PJT), J. Lowne, E. Ruiz (both Purdue), M. Atkinson, S. Morrison (both Province), L. Szlenzinger (Jefferies), M. Diaz, B. Bromberg, C. Kim (all FTI), G. Coutts (Houlihan) re: OxyContin only scenario.	1.50
07/14/20	JD	Call with M. Diaz (FTI), M. Atkinson (Province), L. Szlenzinger (Jefferies), G. Coutts (Houlihan), J. Lowne (Purdue), J. Turner, T. Melvin (PJT) re: business scenarios.	0.50
07/14/20	JD	Correspondence with R. Aleali (Purdue) re: UCC managed care diligence questions.	0.40
07/14/20	SJC	Review and redact Rhodes board meeting minutes in preparation for processing an upload to data room.	1.50
07/14/20	ADD	Research employee with insider titles and aggregate data for processing and upload to the dataroom.	2.40
07/15/20	ADD	Upload diligence production provided by Davis Polk's eDiscovery team to the virtual data room.	2.10
07/15/20	ADD	Prepare files processed by Davis Polk's eDiscovery team for upload to the data room.	1.30
07/15/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	1.00
07/15/20	SJC	Continue to review and redact documents from P drive in preparation for processing an upload to data room.	3.00
07/15/20	JD	Review latest IMS data to be uploaded for creditor	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		advisors.	
07/15/20	ADD	Research employee with insider titles and aggregate data for processing and upload to the dataroom.	2.30
07/15/20	ADD	Compile and upload files provided in response to diligence request for processing and upload to the data room.	1.80
07/16/20	ADD	Compile and prepare materials submitted in response to diligence requests for upload to data room.	1.00
07/16/20	ADD	Identify documents produced in the data room at the request of Davis Polk.	0.80
07/16/20	KM	Advisors meeting with R. Schnitzler (PJT), M. Gibson (Skadden), and interested party Diligence Team re: Project Catalyst.	0.60
07/16/20	JD	Call with J. Lowne, E. Ruiz (both Purdue), J. Turner, T. Melvin (both PJT), M. Atkinson, S. Morrison (both Province), L. Szlenzinger (Jefferies), M. Diaz, B. Bromberg (FTI), G. Coutts (Houlihan) re: distributable value analysis.	1.00
07/16/20	JD	Review questions and proposed responses to FTI diligence questions for the distributable value report.	1.20
07/16/20	JD	Review and comment on follow up responses from the company to certain AHC and UCC follow diligence questions.	0.50
07/16/20	SJC	Continue to review and redact documents from P drive in preparation for processing an upload to data room.	4.00
07/16/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	1.00
07/17/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	3.50
07/17/20	ADD	Compile and prepare materials submitted in response to	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		diligence requests for upload to data room.	
07/20/20	ADD	Review outstanding diligence requests and compile responses for review.	2.40
07/20/20	ADD	Draft approval requests to produce to the Creditor Committees items compiled in response to diligence requests.	1.10
07/20/20	KM	Advisors meeting with R. Schnitzler (PJT), M. Gibson (Skadden), and interested party Diligence Team re: Project Catalyst.	0.50
07/20/20	JD	Correspondence with management and PJT re: scheduling the UCC and management meeting.	0.50
07/20/20	JD	Provide responses to various questions from the AHC and the UCC on the distributable value deck.	0.50
07/20/20	JD	Review responses from management on various questions from the AHC and UCC.	0.30
07/21/20	JD	Review open AHC questions on items to disclose to their committee members.	0.80
07/21/20	JD	Review latest distributable value presentation from the UCC/AHC. Provide comments to management on ability to share with specific creditors.	0.90
07/21/20	JD	Correspondence with management, PJT and Davis Polk re: ability to share UCC/AHC with specific creditors.	0.70
07/21/20	JD	Review IAC diligence presentation in advance of board meeting.	0.50
07/21/20	ADD	Review and draft responses to committee diligence requests.	2.20
07/21/20	ADD	Research prior documents production to determine if specific materials were provided.	1.50
07/21/20	ADD	Compile list of agreements to create list of third-parties	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		for review of items for production.	
07/22/20	ADD	Prepare and upload documents provided by Davis Polk's eDiscovery team to the data room for the UCC.	2.30
07/22/20	ADD	Review data room for materials requested by creditor committee in response to diligence request.	1.70
07/22/20	JD	Participate in the UCC/AHC distributable value presentation to creditors.	1.40
07/22/20	JD	Correspondence with management, Davis Polk and PJT re: sharing the distributable value presentation.	0.40
07/23/20	ADD	Research VDR access error at request of committees members.	0.80
07/23/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	4.00
07/23/20	SJC	Continue to review and redact documents from P drive in preparation for processing an upload to data room.	4.00
07/24/20	ADD	Draft correspondence to request approval to produce diligence request.	0.80
07/24/20	ADD	Review and compile materials submitted in response to diligence request for upload to the data room.	1.90
07/27/20	ADD	Research and document Purdue's tax distribution process for diligence request.	1.90
07/27/20	JD	Partial participation in a call with A. Preis, S. Brauner (both Akin Gump), M. Atkinson (Province), L. Szlenzinger (Jefferies), individual UCC members, J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners), J. Lowne, M. Kesselman, R. Aleali, C. Landau (all Purdue) Re: business update meeting.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
07/27/20	LJD	Prepare for and attend UCC call with A. Preis, S. Brauner (both Akin Gump), M. Atkinson (Province), L. Szlenzinger (Jefferies), individual UCC members, J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners), J. Lowne, M. Kesselman, R. Aleali, C. Landau (all Purdue) Re: business update meeting.	2.30
07/27/20	GJK	Call with A. Preis, S. Brauner (both Akin Gump), M. Atkinson (Province), L. Szlenzinger (Jefferies), individual UCC members, J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners), J. Lowne, M. Kesselman, R. Aleali, C. Landau (all Purdue) Re: business update meeting.	2.00
07/27/20	HSB	Call with J. O'Connell, J. Turner (both PJT), J. DelConte, H. Bhattal, L. Donahue (both AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) RE: board strategic issue questions.	0.70
07/27/20	HSB	Partial participation in a call with A. Preis, S. Brauner (both Akin Gump), M. Atkinson (Province), L. Szlenzinger (Jefferies), individual UCC members, J. O'Connell, J. Turner, T. Melvin (all PJT), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. DelConte, L. Donahue, HS Bhattal, G. Koch (all AlixPartners), J. Lowne, M. Kesselman, R. Aleali, C. Landau (all Purdue) Re: business update meeting.	2.00
07/28/20	KM	Meeting with R. Schnitzler (PJT), M. Gibson (Skadden), interested party diligence team re: Catalyst term sheet feedback.	0.50
07/28/20	KM	Call with R. Shamblen, A. Soma (both Purdue), R.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Date	Consultant	Description of Services	Hours
		Schnitzler (PJT), A. DePalma (AlixPartners), and interested party diligence team re: Ramboll EHS diligence interview for Catalyst.	
07/28/20	KM	Call with interested party re: project Catalyst site visit plan.	0.50
07/28/20	ADD	Call with R. Shamblen, A. Soma (both Purdue), R. Schnitzler (PJT), K. McCafferty (AlixPartners), and interested party diligence team re: Ramboll EHS diligence interview for Catalyst.	1.10
07/28/20	ADD	Research and locate historical Purdue contract to review terms.	0.70
07/29/20	ADD	Research former Purdue employee's role at the room using SAP data.	1.10
07/30/20	ADD	Review and redact Rhodes entities board minutes and resolutions for confidential third party information in preparation for production to the creditor committees.	3.40
07/30/20	JD	Call with J. Turner (PJT), M. Atkinson (Province), M. Diaz (FTI), G. Coutts (Houlihan), L. Szlezinger (Jefferies) re: business development deal.	0.30
07/31/20	JD	Call with J. Turner, T. Melvin (both PJT), M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), J. Lowne, D. Rosen, M. Ronning, and K. Gadski (all Purdue) re: opioid scenarios.	0.70
07/31/20	ADD	Review outstanding diligence requests and compile responsive materials for production.	1.10
Total			139.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Communication with Interested Parties
Client/Matter # 012589.00104

Fee Recap:

Consultant	Hours	Rate	Amount
Barbara J Ferguson	1.80	315.00	567.00
Andrew D DePalma	57.20	515.00	29,458.00
Sam K Lemack	0.70	515.00	360.50
Sam J Canniff	37.50	645.00	24,187.50
Gabe J Koch	2.00	840.00	1,680.00
HS Bhattal	3.40	840.00	2,856.00
Kevin M McCafferty	8.00	950.00	7,600.00
Jesse DelConte	26.10	950.00	24,795.00
Lisa Donahue	2.30	1,195.00	2,748.50
Total Hours & Fees	139.00		94,252.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
07/10/20	ADD	Call A. DePalma and S. Lemack (both AlixPartners) re: MOR quarterly fee calculation discussion.	0.50
07/10/20	NAS	Send data requests to Purdue/TXP for insider payments section of June 2020 MOR.	0.70
07/10/20	SKL	Call A. DePalma and S. Lemack (both AlixPartners) re: MOR quarterly fee calculation discussion.	0.50
07/13/20	SKL	Call with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to review reporting process for insider payments section of MOR.	0.50
07/13/20	SKL	Call with C. MacDonald (Purdue), M. Hartley, S. Lemack, N. Simon (all AlixPartners) to discuss indemnification payment reporting for June 2020 MOR.	0.30
07/13/20	MH	Call with M. Hartley, N. Simon (both AlixPartners) to review Purdue indemnification payment reporting for June 2020 MOR.	0.40
07/13/20	MH	Call with C. MacDonald (Purdue), M. Hartley, S. Lemack, N. Simon (all AlixPartners) to discuss indemnification payment reporting for June 2020 MOR.	0.30
07/13/20	NAS	Call with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to review reporting process for insider payments section of MOR.	0.50
07/13/20	NAS	Analyze indemnification payments for insider payments section of June 2020 MOR.	1.70
07/13/20	NAS	Call with M. Hartley, N. Simon (both AlixPartners) to review Purdue indemnification payment reporting for June 2020 MOR.	0.40
07/13/20	NAS	Call with C. MacDonald (Purdue), M. Hartley, S. Lemack, N. Simon (all AlixPartners) to discuss indemnification payment reporting for June 2020 MOR.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Date	Consultant	Description of Services	Hours
07/13/20	ADD	Call with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to review reporting process for insider payments section of MOR.	0.50
07/14/20	SKL	Review and reconcile Indemnatee firm payments for the June MOR.	0.90
07/14/20	HSB	Review MOR files prepared by S. Lemack (AlixPartners).	0.80
07/15/20	SKL	Meeting with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to walk through insider payments MOR process.	0.30
07/15/20	NAS	Consolidate all data sources into insider payments section of June 2020 MOR.	0.90
07/15/20	NAS	Meeting with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to walk through insider payments MOR process.	0.30
07/15/20	NAS	Review insider payments section of June 2020 MOR for accuracy.	0.60
07/15/20	ADD	Meeting with A. DePalma, S. Lemack, N. Simon (all AlixPartners) to walk through insider payments MOR process.	0.30
07/16/20	JD	Review draft June financials for the MOR.	0.20
07/17/20	JD	Review and sign off on draft MOR.	0.40
07/17/20	ADD	Compile MOR sections and Prepare June MOR for signature.	2.30
07/20/20	JD	Review final signed MOR.	0.20
07/30/20	JD	Review and provide comments on OCP reporting package to be filed with the court.	0.30
Total			14.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: U. S. Trustee / Court Reporting Requirements
Client/Matter # 012589.00105

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	3.60	515.00	1,854.00
Sam K Lemack	2.50	515.00	1,287.50
Nate A Simon	5.40	515.00	2,781.00
HS Bhattal	0.80	840.00	672.00
Michael Hartley	0.70	840.00	588.00
Jesse DelConte	1.10	950.00	1,045.00
Total Hours & Fees	14.10		8,227.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/01/20	JD	Call with J. Lowne (Purdue), R. Schnitzler and J. Turner (both PJT) re: business plan refresh.	0.50
07/01/20	JD	Call with J. Turner, J. O'Connell, T. Coleman (all PJT), L. Donahue and J. DelConte (both AlixPartners) re: pre-board meeting discussion.	0.80
07/01/20	JD	Call with J. Turner (PJT) re: timeline and decision tree deliverable.	0.40
07/01/20	GJK	Review of new Mundipharma presentations and potential impact on business model projections.	2.00
07/01/20	GJK	Follow up related to FTI question re: potential progress on transaction process.	0.20
07/01/20	GJK	Review of Mundipharma Business Plan model and potential updates to working capital.	1.50
07/01/20	GJK	Plan and coordination for July Mundipharma diligence.	1.50
07/01/20	GJK	Edits to Mundipharma executive summary based on PJT feedback.	1.20
07/01/20	LJD	Call with J. Turner, J. O'Connell, T. Coleman (all PJT), L. Donahue and J. DelConte (both AlixPartners) re: pre-board meeting discussion.	0.80
07/01/20	KM	Update DD tracker to reflect new uploads re: Project Catalyst.	0.50
07/01/20	KM	Call with R. Schnitzler (PJT) re: interview process and management.	0.30
07/01/20	KM	Log interview inquiries to DD tracker re: Project Catalyst.	0.20
07/01/20	KM	Log interview inquiries, update diligence tracker and circulate to team re: Project Catalyst.	1.10
07/01/20	JD	Review timeline and items necessary for business plan refresh from J. Lowne. Provide comments re: same.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/01/20	JD	Review correspondence from management and Davis Polk re: payment of prepetition monies owed versus set-off.	0.30
07/01/20	JD	Review PBC value comparison to be shared with Duff & Phelps.	0.20
07/01/20	JD	Finalize draft attrition analysis in response to UCC diligence questions. Correspondence with J. Lowne (Purdue) re: same.	0.60
07/01/20	JD	Update latest professional fee tracker and forecast for 2020.	0.50
07/01/20	KM	Coordinate and manage expedited legal document review with Skadden and A&P re: Project Catalyst.	0.60
07/01/20	KM	Update interested parties diligence teams re: Project Catalyst interviews.	0.60
07/01/20	KM	Manage VDR document flow and communications re: Project Catalyst.	1.30
07/01/20	KM	Call with W. DiNicola (Purdue) re: finance documents for VDR.	0.50
07/01/20	KM	Update DD tracker to reflect new uploads re: Project Catalyst.	0.20
07/01/20	KM	Interview prep call with D. Fogel, W. DiNicola (both Purdue) re: Project Catalyst.	0.50
07/01/20	KM	Manage VDR document flow and communications re: Project Catalyst.	0.80
07/02/20	KM	VDR updating and review re: Project Catalyst.	0.60
07/02/20	KM	Analysis and response proposal in collaboration with R. Shamblen (Purdue) re: Project Catalyst environmental inquiry by Ramboll.	1.30
07/02/20	KM	Analysis in collaboration with R. Shamblen (Purdue) re: procurement commitments for VDR.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/02/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.10
07/02/20	KM	Analysis re: financial responses and edits for Project Catalyst.	0.90
07/02/20	KM	Analysis re: employee tenure tracking for Project Catalyst.	1.00
07/02/20	KM	Update DD tracker to reflect document changes re: Project Catalyst.	0.80
07/02/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, and W. DiNicola (both Purdue) re: Review new finance due diligence questions and compilation of responsive materials.	1.00
07/02/20	KM	VDR response management re: Project Catalyst.	0.50
07/02/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	1.10
07/02/20	KM	Communicate VDR tracker and progress to Bidders re: Project Catalyst.	0.40
07/02/20	KM	Create and track VDR changes and responses re: Project Catalyst VDR tracking tool.	1.50
07/02/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), D. Fogel, and W. DiNicola (both Purdue) re: Review new finance due diligence questions and compilation of responsive materials.	1.00
07/02/20	JD	Correspondence with J. Lowne (Purdue) re: 2021 budget process.	0.20
07/02/20	JD	Call with R. Schnitzler, J. Turner, J. Arsic (all PJT) G. Koch, and J. DelConte (both AlixPartners) re: IAC diligence report.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/02/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: follow up on IAC diligence call.	0.20
07/02/20	JD	Review draft business development licensing agreement.	0.50
07/02/20	JD	Correspondence with FTI and PJT re: delayed bankruptcy emergence scenario presentation.	0.40
07/02/20	JD	Call with L. Donahue, J. DelConte (all AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman (Purdue) re: planning for call with the Board.	1.20
07/02/20	JD	Call with R. Aleali (Purdue) re: outstanding diligence requests.	0.20
07/02/20	JD	Call with E. Vonnegut (Davis Polk) re: board pre-call follow up.	0.20
07/02/20	JD	Correspondence with Davis Polk and PJT re: setting up a call to discuss upcoming board meeting.	0.60
07/02/20	LJD	Call with L. Donahue, J. DelConte (all AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman (Purdue) re: planning for call with the Board.	1.20
07/02/20	GJK	Call with R. Schnitzler, J. Turner, J. Arsic (all PJT) G. Koch, and J. DelConte (both AlixPartners) re: IAC diligence report.	0.50
07/02/20	GJK	Call with B. Kudlek (Mundipharma Tech Ops) to discuss Mundipharma Tech Ops.	1.00
07/02/20	GJK	Prepare and follow up for Tech Ops call, including review of COGs and Malta business plan.	2.20
07/02/20	GJK	Call with PJT to discuss edits to draft Mundipharma report.	0.60
07/02/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re:	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		follow up on IAC diligence call.	
07/02/20	GJK	Finalize draft report edits and share with L Donahue and J DelConte (both AlixPartners).	0.30
07/02/20	GJK	Preparation for Mundipharma diligence including review of HL questions for Deutsche Bank and review of updates presentations.	1.80
07/03/20	LJD	Prepare for and attend call with J. DelConte, L. Donahue (both AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) and Purdue board members re: go forward case progress.	1.80
07/03/20	JD	Call with J. DelConte, L. Donahue (both AlixPartners), T. Coleman, J. O'Connell, J. Turner (all PJT), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) and Purdue board members re: go forward case progress.	1.70
07/03/20	JD	Review materials in advance of Board meeting.	0.40
07/03/20	JD	Call with R. Aleali (Purdue) re: post-call follow ups.	0.20
07/03/20	JD	Review and provide comments on updated IAC diligence report.	1.80
07/06/20	JD	Review side-by-side per diligence sharing request. Correspondence with PJT and Davis Polk re: same.	0.50
07/06/20	JD	Correspondence with R. Aleali and C. George (both Purdue) re: monitor requests.	0.40
07/06/20	JD	Create a diligence tracker for the latest monitor requests.	0.70
07/06/20	JD	Review materials provided by the managed care team in response to requests from the monitor.	3.10
07/06/20	JD	Prepare written responses to business plan diligence questions from Secretary Vilsack.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/06/20	JD	Correspondence with J. Turner, R. Schnitzler (both PJT), J. Lowne and E. Ruiz (both Purdue) re: monitor diligence requests.	0.30
07/06/20	JD	Review proposed questions and responses for Board discussion from PJT. Provide comments and additions re: same.	0.80
07/06/20	JD	Review executed One Stamford Realty documents.	0.40
07/06/20	JD	Review memo from K. Buckfire (Board Member).	0.60
07/06/20	ADD	Review June liabilities subject to compromise spreadsheet for errors.	1.40
07/06/20	ADD	Update liabilities subject to compromise calculation model for June.	2.80
07/06/20	KM	Summarize regulatory documents for R. Shamblen (Purdue) re: response to Ramboll inquiries.	2.20
07/06/20	KM	Summarize EHS documents for R. Shamblen (Purdue) re: response to Ramboll inquiries.	0.50
07/06/20	KM	Analysis and document review re: Project Catalyst environmental.	1.60
07/06/20	KM	Manage VDR documents and plan/book team communications re: Project Catalyst.	0.40
07/06/20	KM	Call with D. Lundie (Purdue) and R. Schnitzler (PJT) re: response approach for open diligence questions.	0.60
07/06/20	KM	Compile raw materials required response re: due diligence inquiry.	1.10
07/06/20	KM	Call with R. Schnitzler (PJT) re: responses.	0.30
07/06/20	KM	Compile raw materials required response re: third party diligence inquiry.	0.20
07/06/20	KM	Prepare and research responses re: Project Catalyst diligence inquiries.	0.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/06/20	KM	Assess and add new inquiries to VDR tracker re: Project Catalyst.	0.60
07/06/20	NAS	Mundipharma LAM diligence call with R. Singh (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other diligence advisors.	1.20
07/06/20	NAS	Correspondence with other advisors involved in Mundipharma diligence re: upcoming meetings.	0.90
07/06/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to discuss recent Mundipharma diligence developments and upcoming meetings.	1.00
07/06/20	NAS	Review Mundipharma diligence materials provided by Huron for meetings during weeks of 6/22 and 6/29.	2.50
07/06/20	NAS	Review revised Executive Summary section of Mundipharma diligence report.	0.40
07/06/20	GJK	Mundipharma LAM diligence call with R. Singh (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other diligence advisors.	1.20
07/06/20	GJK	Prep for R. Singh (Mundipharma) call re: LAM region.	0.50
07/06/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss recent Mundipharma diligence developments and upcoming meetings.	1.00
07/06/20	GJK	Email and follow up with Huron re: Deutsch Bank, ManRev and LEK, including review of prior question lists provided to Huron, review HL proposed DB questions.	1.30
07/06/20	GJK	Review recent posted material and prep for discussion of updates to Mundipharma model with N. Simon (AlixPartners).	3.00
07/06/20	IA	Update Avrio dashboard for June results.	1.50
07/07/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re:	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		IAC diligence.	
07/07/20	NAS	Discussion with G. Koch and N. Simon (both AlixPartners) re: Mundipharma diligence status and priorities for day.	0.60
07/07/20	NAS	Transform Mundipharma Europe product profitability data provided by company and match P&L format across different reports.	1.60
07/07/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to review comparison of Mundipharma product profitability projections vs. current draft of model.	0.70
07/07/20	NAS	Transform Mundipharma LAM product profitability data provided by company.	0.40
07/07/20	NAS	Review differences in Mundipharma Europe product-level projections for specific P&L items and document findings.	2.40
07/07/20	GJK	Review and edits for group emails and questions to Mundipharma from Financial Advisor group.	1.50
07/07/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) re: Mundipharma diligence status and priorities for day.	0.60
07/07/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to review comparison of Mundipharma product profitability projections vs. current draft of model.	0.70
07/07/20	GJK	Plan and coordinate next steps in diligence process based on revised timeline and meeting schedules from Mundipharma.	2.80
07/07/20	GJK	Identify next phase model upgrades for Mundipharma business plan model and provide example.	1.80
07/07/20	NAS	Correspondence with Mundipharma diligence advisors re: upcoming meetings and question lists.	0.70
07/07/20	LJD	Participate in special committee board meeting with J. DelConte and L. Donahue (both AlixPartners).	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/07/20	KM	Build API growth support materials re: partnership opportunity.	1.20
07/07/20	KM	Review of documents re: Project Catalyst.	0.60
07/07/20	KM	Coordinate and manage diligence inquires and team analysis re: Project Catalyst.	1.30
07/07/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Shamblen (Purdue) re: Project Catalyst Supply Chain Requests	1.50
07/07/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), R. Shamblen re: Project Catalyst Supply Chain Requests.	1.50
07/07/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence.	0.20
07/07/20	JD	Prepare for and participate in special committee board meeting with J. DelConte and L. Donahue (both AlixPartners).	1.10
07/07/20	JD	Provide updated professional fee estimates to management for June month end estimates.	0.40
07/07/20	JD	Correspondence with C. George (Purdue) and D. Gentin Stock (Dechert) re: Secretary Vilsack diligence requests.	0.40
07/07/20	JD	Review updated materials from managed care team re: Secretary Vilsack diligence requests.	2.30
07/07/20	JD	Edit, prepare and send response to Purdue and Dechert re: monitor diligence requests.	1.40
07/07/20	JD	Prepare final documents for production for monitor requests.	0.60
07/07/20	JD	Prepare final set of diligence materials for potential business development deal.	0.40
07/07/20	JD	Call with R. Aleali (Purdue) re: board follow up.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/07/20	JD	Call with J. Feltman, R. Levy (both Duff & Phelps), W. Curran, C. Robertson (both Davis Polk), J. Turner, T. Melvin (both PJT), J. Bucholtz (King & Spalding), M. Florence (Skadden) re: post-emergence org structure.	0.80
07/07/20	JD	Review draft response edits to monitor business plan diligence questions.	0.70
07/07/20	JD	Correspondence with S. Lemack and HS Bhattal (both AlixPartners) re: min cash.	0.30
07/08/20	JD	Review and provide comments and edits to draft IAC diligence report.	2.80
07/08/20	JD	Call with J. Turner (PJT) re: open diligence items.	0.20
07/08/20	JD	Call with J. Lowne (Purdue) re: AlixPartners professional fee discussion.	0.40
07/08/20	JD	Review Project Catalyst analysis in advance of call.	0.30
07/08/20	JD	Review correspondence re: Project Catalyst contract provisions.	0.30
07/08/20	JD	Review the Butrans only scenario in preparing the OxyContin only scenario.	0.40
07/08/20	JD	Review strategic questions to be answered in advance of future board meetings.	0.50
07/08/20	JD	Call with R. Schnitzler, J. Turner (both PJT), J. Doyle, D. Lundie, D. Fogel, K. McCarthy, R. Shamblen (all Purdue) J. DelConte and K. McCafferty (both AlixPartners) re: Project Catalyst.	0.90
07/08/20	JD	Call with R. Aleali (Purdue) re: board discussion follow ups.	0.60
07/08/20	KM	Analysis re: finance diligence requests.	1.00
07/08/20	KM	Update DD tracker for PPLP review and round 2 planning re: Project Catalyst.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/08/20	KM	Call with R. Schnitzler, J. Turner (both PJT), J. Doyle, D. Lundie, D. Fogel, K. McCarthy, R. Shamblen (all Purdue) J. DelConte and K. McCafferty (both AlixPartners) re: Project Catalyst.	0.90
07/08/20	KM	Coordinate and manage expedited legal document review with Skadden and A&P re: Project Catalyst.	0.40
07/08/20	KM	Update and refine re: Project Catalyst VDR tracker.	1.00
07/08/20	KM	Diligence tracker updates and team communications re: Project Catalyst.	1.60
07/08/20	KM	Analysis and slide creation re: prep for partnership growth opportunity discussion points.	0.80
07/08/20	KM	Analysis re: Project Catalyst environmental history and impact for RT.	0.80
07/08/20	KM	Review of regulatory documents re: Project Catalyst.	0.90
07/08/20	SKL	Review and reconcile the Rhodes weekly sales report provided by P. Phouthasone (Purdue) and formatted accordingly for production purposes.	0.80
07/08/20	SKL	Finalize updates to the April non-PEO Flash report based on the feedback provided and circulated to R. Aleali (Purdue) for final sign-off.	1.30
07/08/20	SKL	Review and reconcile the May financial presentation and began formatting accordingly for the May PEO Flash report.	2.30
07/08/20	SKL	Finalize review of the May financial presentation as well as updates to the May PEO Flash report and circulated internally for final sign-off.	2.10
07/08/20	SKL	Review and reconcile the Purdue weekly sales report provided by E. Nowakowski (Purdue) and formatted accordingly for production purposes.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/08/20	GJK	Begin outline for revised/final Mundipharma report based on new data and diligence.	3.00
07/08/20	GJK	Draft and send email to Huron re: LEK participation in diligence process.	1.20
07/08/20	GJK	Review provided material for potential impact on cash and working capital.	1.50
07/08/20	GJK	Update diligence planning and potential next steps for monetizing IACs and timing.	1.30
07/08/20	GJK	Review of LAM region market by product profitably compared to original budget.	1.00
07/08/20	NAS	Review comments to latest draft of Mundipharma diligence report.	1.20
07/08/20	NAS	Transform Mundipharma LAM product profitability data provided by company.	2.40
07/08/20	NAS	Detail takeaways from analysis of Mundipharma LAM product profitability data.	1.60
07/08/20	NAS	Revise latest draft of Mundipharma diligence report following comments from J. DelConte (AlixPartners).	1.20
07/09/20	NAS	Diligence call with L. Reber (Mundipharma Compliance), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors.	0.50
07/09/20	NAS	Prepare for diligence call with L. Reber (Mundipharma Compliance).	0.30
07/09/20	NAS	Discussions with G. Koch and N. Simon (both AlixPartners) re: takeaways from Mundipharma Compliance call and cases presented in latest draft of report.	1.40
07/09/20	NAS	Review downside case included in Mundipharma business plan model.	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/09/20	NAS	Revise latest draft of Mundipharma diligence report following comments from J. DelConte (AlixPartners).	3.50
07/09/20	NAS	Calls with G. Koch and N. Simon (both AlixPartners) to review latest draft of Mundipharma report and strategize best way to incorporate new information to next iteration of model.	0.50
07/09/20	NAS	Call with J. Arsic (PJT) to discuss current draft of Mundipharma diligence report.	0.30
07/09/20	NAS	Review materials provided on Mundipharma licensing agreements.	0.60
07/09/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence report.	0.20
07/09/20	GJK	Calls with G. Koch and N. Simon (both AlixPartners) to review latest draft of Mundipharma report and strategize best way to incorporate new information to next iteration of model.	0.50
07/09/20	GJK	Diligence call with L. Reber (Mundipharma Compliance), G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors.	0.50
07/09/20	GJK	Follow up and coordinate on updates to Mundipharma draft report.	1.20
07/09/20	GJK	Review Celltrion summary provided by Mundipharma.	0.50
07/09/20	GJK	Discussions with G. Koch and N. Simon (both AlixPartners) re: takeaways from Mundipharma Compliance call and cases presented in latest draft of report.	1.40
07/09/20	GJK	Plan out model revisions based on new market/product level data for Mundipharma model.	2.00
07/09/20	GJK	Continue outlining final draft Mundipharma report based on new data and diligence calls.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/09/20	LJD	Prepare for and participate in call with T. Coleman, J. O'Connell, J. Turner (all PJT), K. Buckfire, J. Dubel (both Purdue Board members), L. Donahue and J. DelConte (both AlixPartners) re: case progress and plan to get to emergence.	1.10
07/09/20	LJD	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. DelConte and L. Donahue (both AlixPartners) re: case status and strategy go forward.	1.40
07/09/20	KM	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), D. Lundie, D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler (PJT), and others re: Project Catalyst.	1.50
07/09/20	KM	Analysis re: procurement commitments through 2021.	0.10
07/09/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Shamblen, and A. Nadeau (both Purdue) re: Project Catalyst NRM Supply discussion.	0.90
07/09/20	KM	Analysis re: Catalyst supply chain responses.	0.40
07/09/20	KM	Create response for Rhodes review re: remediation effort summary for Project Catalyst.	0.30
07/09/20	KM	Prep materials for VDR internal working team meeting re: Project Catalyst.	0.40
07/09/20	KM	Analysis and document generation re: raw materials inquiries for Project Catalyst.	0.80
07/09/20	KM	Analysis for quota and productivity data re: inquiry for Catalyst.	1.20
07/09/20	KM	Call with D. Fogel (Purdue) re: finance analyses for Catalyst.	0.90
07/09/20	KM	Call with R. Schnitzler (PJT) and interested party re:	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Project Catalyst clarifications and bid process.	
07/09/20	KM	Create and circulate trackers to various parties re: Project Catalyst.	0.50
07/09/20	KM	Update tracker and responses re: Project Catalyst.	1.00
07/09/20	KM	Create documents re: procurement commitments for Project Catalyst.	1.00
07/09/20	KM	Coordinate and process diligence requests re: Project Catalyst.	0.90
07/09/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Shamblen, and A. Nadeau (both Purdue) re: Project Catalyst NRM Supply discussion.	0.90
07/09/20	ADD	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), D. Lundie, D. Fogel, R. Shamblen, K. McCarthy (all Purdue), R. Schnitzler (PJT), and others re: Project Catalyst.	1.50
07/09/20	JD	Review post-emergence governance structure presentations.	0.50
07/09/20	JD	Call with M. Huebner, C. Robertson (both Davis Polk), T. Coleman, J. O'Connell, J. Turner (all PJT), C. Landau, M. Kesselman, J. Lowne, R. Aleali (all Purdue), J. DelConte and L. Donahue (both AlixPartners) re: case status and strategy go forward.	1.40
07/09/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC diligence report.	0.20
07/09/20	JD	Call with T. Coleman, J. O'Connell, J. Turner (all PJT), K. Buckfire, J. Dubel (both Purdue Board members), L. Donahue and J. DelConte (both AlixPartners) re: case progress and plan to get to emergence.	1.00
07/09/20	JD	Call with J. DelConte, A. DePalma, K. McCafferty (all AlixPartners), D. Lundie, D. Fogel, R. Shamblen, K.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCarthy (all Purdue), R. Schnitzler (PJT), and others re: Project Catalyst.	
07/09/20	JD	Prepare summary of severance per employee by different Purdue operating company.	0.50
07/09/20	JD	Call with J. Turner, R. Schnitzler, T. Melvin (all PJT), J. Lowne, E. Ruiz (all Purdue) re: OxyContin only scenario.	0.70
07/09/20	JD	Draft response to Monitor question on business plan presentation to send to C. George (Purdue).	0.40
07/10/20	JD	Continue review of draft IAC diligence report. Edit and provide comments to same.	2.30
07/10/20	JD	Correspondence with Purdue re: Project Catalyst contract analysis.	0.30
07/10/20	JD	Review draft analysis created by J. Lowne and E. Ruiz (both Purdue) re: OxyContin only scenario. Correspondence with management re: same.	2.50
07/10/20	JD	Prepare agenda for internal AlixPartners weekly update call.	0.30
07/10/20	JD	Participate in informal board discussion on post-emergence governance structure including J. DelConte and L. Donahue (both AlixPartners).	1.40
07/10/20	ADD	Call with J. Doyle (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst contract analysis.	0.50
07/10/20	KM	Create and circulate trackers re: Project Catalyst.	0.30
07/10/20	KM	VDR tracker management re: Project Catalyst.	0.20
07/10/20	KM	Call with R. Shamblen (Purdue) re: manufacturing campaign for Catalyst.	0.10
07/10/20	KM	Analysis re: manufacturing campaign for Catalyst.	1.20
07/10/20	KM	Call with D. Lundie, D. Fogel, R. Shamblen (Purdue), R. Schnitzler (PJT) re: diligence inquiries.	1.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/10/20	KM	Team prep and analysis re: diligence inquiries and data links.	1.00
07/10/20	KM	VDR tracker management re: Project Catalyst.	1.00
07/10/20	KM	Call with R. Shamblen (Purdue) re: manufacturing campaign for Catalyst.	0.20
07/10/20	KM	Update tracker and responses re: Project Catalyst.	0.50
07/10/20	KM	Call with J. Doyle (Purdue), A. DePalma, K. McCafferty (both AlixPartners) re: Catalyst contract analysis.	0.50
07/10/20	KM	Analysis re: Oct 2020 inventory position for Project Catalyst	0.30
07/10/20	LJD	Participate in informal board discussion on post-emergence governance structure including J. DelConte and L. Donahue (both AlixPartners).	1.40
07/10/20	SKL	Finalize remaining updates to the May PEO-Flash report and circulated to J. Lowne (Purdue) and R. Aleali (Purdue) for final sign-off.	1.40
07/10/20	GJK	Revise Mundipharma draft interim report based on edits from J DelConte (AlixPartners). Review final edits before document released back to PJT.	1.70
07/10/20	GJK	Plan and coordinate for upcoming Mundipharma advisor calls.	2.00
07/10/20	GJK	Review of newly posted Mundipharma materials.	3.00
07/10/20	NAS	Revise draft of Mundipharma diligence report following subsequent comments from J. DelConte (AlixPartners).	1.70
07/10/20	NAS	Analyze and transform revised product-level raw data provided by Mundipharma for next iteration of model.	2.30
07/13/20	NAS	Analyze and transform revised Europe product-level raw data provided by Mundipharma for next iteration of model.	3.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/13/20	NAS	Review new Mundipharma diligence materials provided by Huron.	1.30
07/13/20	GJK	Prepare for business development and Deutsch Bank calls for Mundipharma diligence calls, including review of Biosimilar and Specialty products.	2.00
07/13/20	GJK	Plan and coordinate Mundipharma diligence updates related to draft report revisions.	2.50
07/13/20	GJK	Analyze cost of goods comparison between business plan updates.	2.80
07/13/20	KM	Update and circulate VDR tracker re: Project Catalyst.	0.50
07/13/20	KM	Analysis of Rhodes stand-alone financial model re: Project Catalyst.	1.60
07/13/20	KM	Continue financial analysis re: diligence inquiries.	0.90
07/13/20	KM	Meeting with W. DiNicola, D. Fogel (both Purdue), R. Schnitzler (PJT) and A. DePalma (AlixPartners) re: Repatriate finance inquiries.	0.60
07/13/20	KM	Call with W. DiNicola, D. Fogel (both Purdue), and A. DePalma (AlixPartners) re: prep for Repatriate discussion.	0.70
07/13/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst diligence process.	0.40
07/13/20	KM	Financial analysis re: diligence inquiries.	1.40
07/13/20	KM	Assess and add new inquiries to VDR tracker re: Project Catalyst.	0.70
07/13/20	ADD	Call with W. DiNicola, D. Fogel (both Purdue), and K. McCafferty (AlixPartners) re: prep for Repatriate discussion.	0.70
07/13/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence process.	
07/13/20	ADD	Meeting with W. DiNicola, D. Fogel (both Purdue), R. Schnitzler (PJT) and K. McCafferty (AlixPartners) re: Repatriate finance inquiries.	0.60
07/13/20	JD	Call with J. Lowne (Purdue) re: business sensitivity scenario.	0.20
07/13/20	JD	Correspondence with Purdue team re: post-petition donation information and reviewing files produced.	1.10
07/13/20	JD	Edit files to be responsive to UCC managed care diligence questions. Circulate for review and sign off.	0.80
07/13/20	JD	Review final OxyContin only scenarios and pre-reads for the UCC.	1.70
07/13/20	JD	Call with C. Robertson (Davis Polk) re: political contribution motion.	0.20
07/13/20	JD	Review draft May monthly flash report.	0.70
07/13/20	JD	Review draft Nalmafene report to be shared with creditor advisors.	0.20
07/13/20	JD	Review data on betadine in kind donations.	0.30
07/13/20	JD	Review responses provided to previous strategic planning questions.	0.60
07/13/20	JD	Review materials provided re: political memberships and dues.	0.40
07/13/20	JD	Correspondence with Davis Polk re: UCC political contribution response information.	0.40
07/14/20	JD	Call with J. Lowne, E. Ruiz (both Purdue), J. Turner and R. Schnitzler (both PJT) re: business scenario modeling.	0.20
07/14/20	JD	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC diligence.	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/14/20	JD	Call with J. Turner, T. Melvin, R. Schnitzler (all PJT) re: distributable value analysis.	0.70
07/14/20	JD	Review various proposals re: Project Catalyst.	1.50
07/14/20	JD	Review and correspondence with PJT re: restricted cash roll off schedules.	0.60
07/14/20	JD	Review memo re: insurance recoveries.	0.30
07/14/20	JD	Review distributable value presentation put together by the ACH and UCC.	2.30
07/14/20	JD	Review attrition data and calculate as of 6/30. Correspondence with C. DiStefano (Purdue) re: same.	0.70
07/14/20	KM	Circulate revised volume re: Project Catalyst.	0.10
07/14/20	KM	Call with D. Fogel and W. DiNicola (both Purdue) re: volume detail through 2024.	0.30
07/14/20	KM	Review and edit re: Rhodes dashboard for Board review.	0.40
07/14/20	KM	Call with D. Fogel (Purdue) re: CPP analysis and pricing strategy.	1.00
07/14/20	KM	Analysis re: Project Catalyst inquiries.	0.40
07/14/20	KM	Assess and add new inquiries to VDR tracker re: Project Catalyst.	1.50
07/14/20	KM	Review and coordinate re: RT supply agreements for Catalyst.	1.50
07/14/20	GJK	Calls with G. Koch and N. Simon (both AlixPartners) to discuss current status of case and review takeaways from calls with M. Cerato (Mundipharma) and Deutsche Bank.	1.10
07/14/20	GJK	Call with I McClatchy (Norton Rose) re: Deutsch Bank diligence call.	0.50
07/14/20	GJK	Coordinate and follow up for Mundipharma diligence including calls/emails with financial advisors.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/14/20	GJK	Outline potential upside overall based on call with M Certo and Deutsch Bank on business development opportunities.	2.20
07/14/20	GJK	Call with Deutsche Bank, G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors to discuss current status of sale process.	1.30
07/14/20	GJK	Diligence call with M. Cerato (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other diligence advisors to review Mundipharma business development initiatives.	1.00
07/14/20	NAS	Check transformed Mundipharma Europe data for accuracy.	1.00
07/14/20	NAS	Calls with G. Koch and N. Simon (both AlixPartners) to discuss current status of case and review takeaways from calls with M. Cerato (Mundipharma) and Deutsche Bank.	1.10
07/14/20	NAS	Diligence call with M. Cerato (Mundipharma), G. Koch, N. Simon (both AlixPartners), and other diligence advisors to review Mundipharma business development initiatives.	1.00
07/14/20	NAS	Call with Deutsche Bank, G. Koch, N. Simon (both AlixPartners), and other Mundipharma diligence advisors to discuss current status of sale process.	1.30
07/14/20	NAS	Analyze and transform revised LAM product-level raw data provided by Mundipharma for next iteration of model.	3.00
07/14/20	GJK	Call with J. DelConte and G. Koch (both AlixPartners) re: IAC diligence.	0.20
07/14/20	HSB	Review Purdue P&L forecasts by segment.	0.50
07/15/20	NAS	Analyze and transform revised LAM-META product-level raw data provided by Mundipharma for next iteration of model.	2.40
07/15/20	NAS	Check transformed all Mundipharma LAM data relative to	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		source provided by company.	
07/15/20	NAS	Analyze and transform revised LAM-Asia product-level raw data provided by Mundipharma for next iteration of model.	2.50
07/15/20	IA	Review and confirm projected 2022 payment for LTRP amounts based on scenarios requested by WTW.	0.70
07/15/20	GJK	Review Mundipharma diligence responses and develop next steps.	2.00
07/15/20	KM	Update and circulate VDR tracker re: Project Catalyst.	0.30
07/15/20	KM	Meeting with R. Sublett (AlixPartners) re: CPP analysis for ClarusONE Oxy-IR product pricing.	0.40
07/15/20	KM	Call with J. DelConte (AlixPartners) re: Project Catalyst bid process.	0.30
07/15/20	KM	Analysis re: Project Catalyst offers.	1.40
07/15/20	KM	Call with D. Fogel (Purdue) re: Catalyst volume scenarios.	0.80
07/15/20	KM	Summarize and communicate findings re: Catalyst analysis.	0.80
07/15/20	KM	Analysis re: API pricing analysis by Bidder for Project Catalyst 2021-2024.	2.70
07/15/20	KM	Call with R. Schnitzler (PJT) re: Project Catalyst bid analysis.	0.30
07/15/20	KM	Analysis re: API supply agreement offers.	1.10
07/15/20	RDS	Meeting with K. McCafferty (AlixPartners) re: CPP analysis for ClarusONE Oxy-IR product pricing.	0.40
07/15/20	JD	Call with J. Turner, T. Melvin (both PJT), J. Lowne and E. Ruiz (both Purdue) re: business scenarios.	0.20
07/15/20	JD	Call with AHC advisors, UCC advisors, J. Lowne, E. Ruiz (both Purdue), J. Turner, T. Melvin, R. Schnitzler (all PJT)	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		re: distributable value presentation.	
07/15/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst.	0.20
07/15/20	JD	Call with R. Schnitzler (PJT) re: Project Catalyst.	0.20
07/15/20	JD	Review updated business scenarios from management for the distributable value presentation.	2.80
07/15/20	JD	Review updated change in working capital calculation for the updated business scenarios.	0.50
07/15/20	JD	Create initial list of post-petition donations to send around to the team for review.	1.30
07/15/20	JD	Review draft outline for the business plan refresh presentation.	0.60
07/15/20	JD	Review Rhodes Tech analysis per open diligence questions.	0.40
07/15/20	JD	Review additional materials re: Project Catalyst.	0.50
07/15/20	JD	Call with K. McCafferty (AlixPartners) re: Project Catalyst bid process.	0.30
07/16/20	JD	Call with D. Fogel (Purdue) re: recent attrition rates.	0.20
07/16/20	JD	Call with R. Aleali (Purdue) re: distributable value presentation.	0.30
07/16/20	JD	Call with J. Turner (PJT) re: distributable value analysis.	0.30
07/16/20	JD	Review Akin fee statement and correspondence with Davis Polk re: same.	0.30
07/16/20	JD	Review Gilbert insurance presentation and correspondence with C. Ricarte (Purdue) re: same.	0.50
07/16/20	JD	Finalize draft strategic question response draft and circulate to DPW and PJT for comments.	2.30
07/16/20	JD	Review and provide comments on draft business plan refresh presentation.	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/16/20	JD	Review and edit AHC due diligence responses re: minimum cash.	0.70
07/16/20	JD	Review Project Catalyst proposal analyses.	0.40
07/16/20	KM	Meeting with R. Shamblen (Purdue) re: vendor contract prioritization.	0.50
07/16/20	KM	Analysis and communication re: Vendor contracts for RT.	0.70
07/16/20	KM	Bid offer analysis and summary re: Project Catalyst.	2.10
07/16/20	KM	Update and circulate VDR tracker re: Project Catalyst.	1.10
07/16/20	KM	Analysis re: prioritization of supply agreements for Project Catalyst VDR.	1.20
07/16/20	KM	Call with D. Fogel (Purdue) re: June 2020 dashboard.	0.30
07/16/20	KM	Analysis re: Rhodes Board dashboard.	0.80
07/16/20	ADD	Review list of material contracts and cross reference with contract work previously conducted by outside counsel.	2.50
07/16/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to discuss priorities for day and plan for revised Mundipharma model.	0.40
07/16/20	GJK	Review of update Malta model with revised product by market data.	1.50
07/16/20	GJK	Update Mundipharma diligence planning and next steps.	2.00
07/16/20	NAS	Compare versions of Mundipharma business plan model provided by management and investigate changes.	0.60
07/16/20	NAS	Respond to question from J. Arsic (PJT) about price/volume analysis provided by management.	0.50
07/16/20	NAS	Analyze and transform revised Canada product-level and Central Function raw data provided by Mundipharma for next iteration of model.	2.60
07/16/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to	0.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		discuss priorities for day and plan for revised Mundipharma model.	
07/16/20	NAS	Check transformed data against raw sources for accuracy and resolve discrepancies.	1.40
07/16/20	NAS	Build second iteration of Mundipharma business plan model based on revised materials provided by management.	1.50
07/17/20	NAS	Review new Mundipharma diligence materials provided by management/Huron.	1.10
07/17/20	NAS	Call with G. Koch, N. Simon (both AlixPartners) to review new version of Mundipharma business plan model.	0.70
07/17/20	NAS	Revisions to new version of Mundipharma model based on discussion with G. Koch (AlixPartners).	0.40
07/17/20	GJK	Review revised Invokana documents provided by Mundipharma.	2.50
07/17/20	GJK	Review updates Mundipharma diligence responses from S. Jamieson (Management Revisions).	0.60
07/17/20	GJK	Call with G. Koch, N. Simon (both AlixPartners) to review new version of Mundipharma business plan model.	0.70
07/17/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), K. McCafferty (AlixPartners) re: Catalyst operations and supply chain diligence.	1.20
07/17/20	ADD	Review Rhodes contracts in preparation for Project Catalyst diligence requests.	0.20
07/17/20	ADD	Call with R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), D. Lundie, R. Shamblen, D. Fogel, J. Lowne, R. Aleali (all Purdue), M. Gibson (Skadden) J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: Project Catalyst.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/17/20	KM	Analysis re: Project Catalyst summary.	1.30
07/17/20	KM	Advisors call with R. Aleali, K. McCarthy (both Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: Project Catalyst transaction documents.	0.80
07/17/20	KM	Refine prioritized list re: Project Catalyst supply agreements review.	0.60
07/17/20	KM	Final prioritization and review prep re: Project Catalyst supply contract review.	0.70
07/17/20	KM	Manage VDR changes re: Project Catalyst.	0.10
07/17/20	KM	Call with R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), D. Lundie, R. Shamblen, D. Fogel, J. Lowne, R. Aleali (all Purdue), M. Gibson (Skadden) J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: Project Catalyst.	1.40
07/17/20	KM	Call with R. Schnitzler (PJT) re: Project Catalyst summaries.	0.10
07/17/20	KM	Coordinate operations team activities re: Project Catalyst diligence.	0.40
07/17/20	KM	Call with J. Turner, R. Schnitzler (both PJT), M. Gibson, R. Schlossberg (both Skadden), J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst.	0.60
07/17/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	1.20
07/17/20	KM	Analysis re: Project Catalyst supply contract review.	0.70
07/17/20	JD	Call with R. Schnitzler, J. Turner (both PJT), C. Robertson (Davis Polk), D. Lundie, R. Shamblen, D. Fogel, J. Lowne, R. Aleali (all Purdue), M. Gibson (Skadden) J. DelConte, K. McCafferty, A. DePalma (all AlixPartners) re: Project Catalyst.	1.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/17/20	JD	Call with R. Aleali (Purdue) re: Project Catalyst.	0.20
07/17/20	JD	Call with J. Turner, R. Schnitzler (both PJT), M. Gibson, R. Schlossberg (both Skadden), J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst.	0.60
07/17/20	JD	Review updated responses to minimum cash diligence questions.	0.30
07/17/20	JD	Review updated joint distributable value presentation from the AHC and UCC.	1.10
07/17/20	JD	Correspondence with Davis Polk re: production materials.	0.40
07/17/20	JD	Update latest professional fee tracker to provide to Davis Polk.	0.80
07/18/20	JD	Prepare and send around updated donations diligence response.	0.60
07/18/20	JD	Review and provide comments on diligence questions from AHC and UCC.	0.50
07/19/20	JD	Phone call and correspondence with J. McClammy (Davis Polk) and D. Levy and R. Aleali (both Purdue) re: donations.	0.50
07/20/20	JD	Call with R. Aleali (Purdue) re: open diligence items.	0.20
07/20/20	JD	Call with R. Aleali (Purdue) re: upcoming creditor presentation.	0.40
07/20/20	JD	Review comments from management re: donation info in order to update the diligence schedule.	1.10
07/20/20	JD	Review and edit responses to strategic review questions.	0.70
07/20/20	JD	Update strategic issues responses memo for comments from Davis Polk and send it around for final review.	0.90
07/20/20	JD	Review latest draft distributable value presentation from the UCC and AHC.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/20/20	JD	Review initial draft of the management business update presentation for the UCC meeting on Monday.	1.80
07/20/20	JD	Review draft customer program reports to be posted to the data room.	0.40
07/20/20	KM	Coordinate responses re: project Catalyst.	0.20
07/20/20	KM	Call with D. Fogel and W. DeNicola (both Purdue) re: inventory planning reporting requirements and process.	1.00
07/20/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/20/20	KM	Planning re: project Catalyst VDR needs and inquiries.	0.80
07/20/20	KM	Analysis re: API month-end inventory.	0.50
07/20/20	KM	Analysis re: RT reports for VDR.	1.10
07/20/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review and redact documents in response to diligence request for Project Catalyst.	1.00
07/20/20	KM	Call with R. Schnitzler (PJT) re: term sheet response review.	0.20
07/20/20	KM	Manage VDR and inquires re: Project Catalyst round 2.	0.70
07/20/20	KM	Analysis and documentation re: project Catalyst.	1.30
07/20/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/20/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review and redact documents in response to diligence request for Project	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Catalyst.	
07/20/20	NAS	Review new Mundipharma diligence materials provided by management.	0.60
07/20/20	NAS	Add product/market/region-level analyses to second iteration of Mundipharma business plan model.	2.90
07/20/20	NAS	Review LEK non-reliance letter and correspondence with internal Legal team.	0.70
07/20/20	NAS	Review prior price/volume data and Diabetes segment projections relative to latest Mundipharma model provided.	1.20
07/20/20	NAS	Add product-level benchmarking analyses to new iteration of Mundipharma business plan model.	1.70
07/20/20	GJK	Prep for Special Committee call re Settlement related items.	1.00
07/20/20	GJK	Review and coordinate with Legal re: the review of LEK non-reliance letter.	0.70
07/20/20	GJK	Review and create question list for Mundiapharma business model including revised management case data.	0.80
07/20/20	GJK	Review Mundipharma documents/answers provided to Advisors.	1.50
07/20/20	GJK	Plan and coordinate for final diligence "push" in August including outline of key outstanding items and next steps.	2.00
07/20/20	LJD	Review and comment on draft answers to board strategic questions.	0.90
07/21/20	LJD	Prepare for and attend special committee call (partial participation).	1.10
07/21/20	LJD	Review and discuss status deck for board meeting re: settlement progress.	0.80
07/21/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		discuss developments in Mundipharma diligence process and current priorities.	
07/21/20	GJK	Outline analysis for bridge/walk between Mundipharma business cases based on Mundipharma 2.0 model.	2.50
07/21/20	GJK	Plan follow up activity based on Special Committee and Advisor call including streamline version of draft interim report.	1.50
07/21/20	GJK	Review question list to Mundipharma Treasurer and emails with N. Simon (AlixPartners) for follow up.	0.70
07/21/20	GJK	Walkthrough updates Mundi Model 2.0 from N Simon (AlixPartners).	1.00
07/21/20	GJK	Call with G. Koch and J. DelConte (both AlixPartners) re: IAC discussion with the special committee.	0.20
07/21/20	NAS	Add benchmarking analyses for Gross Margin, Selling & Promotion, and Medical Affairs to Mundipharma model.	3.20
07/21/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to discuss developments in Mundipharma diligence process and current priorities.	0.50
07/21/20	NAS	Review and comment on agendas for upcoming diligence meetings.	0.80
07/21/20	NAS	Analyze unallocated costs for each P&L line in latest Mundipharma business plan.	2.40
07/21/20	GJK	Call with J. O'Connell, J. Turner (both PJT), M. Huebner, E. Vonnegut, C. Robertson, B. Kaminetsky (all Davis Polk), G. Koch, HS Bhattal, J. DelConte and L. Donahue (all AlixPartners) re: go forward planning.	0.60
07/21/20	GJK	Call with Special Committee of Purdue Board to discuss Settlement related items.	1.20
07/21/20	GJK	Call with I McClatchey (Norton Rose) to discuss diligence	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		process.	
07/21/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.60
07/21/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst due diligence status update.	0.30
07/21/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.80
07/21/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.60
07/21/20	KM	Call with D. Lundie (Purdue) and R. Schnitzler (PJT) re: call debrief.	0.30
07/21/20	KM	Call with D. Lundie (Purdue), R. Schnitzler (PJT), diligence team re: term sheet feedback.	0.60
07/21/20	KM	Analysis re: Project Catalyst proposal.	0.40
07/21/20	KM	Meeting with R. Schnitzler (PJT) re: term sheet feedback.	0.60
07/21/20	KM	Continue analysis re: Project Catalyst proposal.	0.50
07/21/20	KM	Meeting with R. Schnitzler (PJT) re: term sheet feedback.	0.70
07/21/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne, K. McCarthy, R. Aleali (all Purdue), Skadden re: Catalyst APA Discussion.	1.90
07/21/20	KM	Analysis re: supply chain and inventory analysis.	1.10
07/21/20	JD	Call with G. Koch and J. DelConte (both AlixPartners) re:	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		IAC discussion with the special committee.	
07/21/20	JD	Prepare for and participate in the special committee board meeting.	1.40
07/21/20	JD	Review final AHC/UCC distributable value presentation.	0.70
07/21/20	JD	Review response from management on open AHC distributable value questions.	0.40
07/21/20	JD	Call with C. Landau, J. Lowne, M. Kesselman, M. Ronning, K. Gadski (all Purdue), J. Turner (PJT) re: OxyContin scenarios.	0.60
07/21/20	JD	Call with R. Aleali, S. Robertson (both Purdue) and J. Turner (PJT) re: Rebranding.	0.40
07/21/20	JD	Call with J. Turner (PJT) re: AHC/UCC presentation.	0.30
07/21/20	JD	Prepare updates professional fee payments to date slide for UCC presentation.	0.70
07/21/20	JD	Prepare responses to open Monitor diligence questions on the latest business plan presentation.	1.20
07/21/20	KM	Call with A. DePalma and K. McCafferty (both AlixPartners) re: Project Catalyst due diligence status update.	0.30
07/21/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.80
07/21/20	KM	Call with D. Lundie (Purdue) and R. Schnitzler (PJT) re: project Catalyst messaging prep.	0.50
07/21/20	KM	Analysis and inquiry tracking re: RT environmental questions.	1.00
07/21/20	KM	Create report re: RT org structure for VDR.	1.20
07/22/20	JD	Review and provide comments on Purdue rebranding	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		memo from S. Robertson (Purdue).	
07/22/20	JD	Correspondence with PJT and management re: UCC call and prep scheduling.	0.50
07/22/20	JD	Correspondence with Davis Polk and management re: reporter inquiry on the MOR.	0.80
07/22/20	JD	Review MOR professional fees and investigate difference in cash versus accrual amounts.	0.50
07/22/20	JD	Call with M. Sharp (Purdue) re: reporter inquiry.	0.20
07/22/20	JD	Call with J. Lowne (Purdue) re: latest UCC deck.	0.20
07/22/20	JD	Participate in Purdue board meeting.	1.30
07/22/20	JD	Call with R. Aleali (Purdue) re: post board meeting follow ups.	0.20
07/22/20	JD	Review and provide comments on draft memo re: creditor negotiations.	0.60
07/22/20	KM	Coordinate environmental diligence responses re: project Catalyst.	1.40
07/22/20	KM	Analysis re: RT crewing and capacity for Catalyst.	1.30
07/22/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst process.	0.40
07/22/20	KM	Review and coordinate action items re: project Catalyst VDR.	0.60
07/22/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/22/20	KM	Call with R. Shamblen (Purdue) re: interview prep for Catalyst.	0.50
07/22/20	KM	Analysis re. value creation opportunities.	1.60
07/22/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, (all	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	
07/22/20	GJK	Review comments from DPW on Mundipharma interim report.	0.60
07/22/20	NAS	Review Purdue business plan update provided to UCC.	0.70
07/22/20	NAS	Analyze non-commercial region product financials in latest budget provided by Mundipharma management.	1.10
07/22/20	NAS	Review new Mundipharma diligence responses from S. Jamieson (Management Revisions) and note additional questions for 7/24 call.	0.60
07/22/20	NAS	Call with G. Koch and N. Simon (both AlixPartners) to review latest iteration of Mundipharma business plan model.	1.50
07/22/20	NAS	Review comments to Mundipharma diligence report provided by Counsel (DPW) and note follow-ups.	1.00
07/22/20	NAS	Build new Net Sales overview page in Mundipharma business plan model.	0.60
07/22/20	GJK	Walkthrough UCC deck update draft to prepare for UCC-Purdue meeting on Monday.	2.50
07/22/20	GJK	Review and assessment of LAM region in light of executive departures (ongoing).	2.00
07/22/20	GJK	Call with G. Koch and N. Simon (both AlixPartners) to review latest iteration of Mundipharma business plan model.	1.50
07/22/20	LJD	Prepare for and attend board call (partial participation).	1.10
07/23/20	LJD	Prepare for and attend board call (partial participation).	1.10
07/23/20	GJK	Call with J Turner (PJT) to discuss diligence report next steps.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/23/20	GJK	Project management including reviewing and responding to G&A questions in model, responses from Huron, prep for call with Mundipharma CEO.	1.50
07/23/20	GJK	Review and assessment of LAM region in light of executive departures (ongoing).	2.50
07/23/20	GJK	Review of growth product data provided by Huron.	1.20
07/23/20	GJK	Review S Jamieson (Management Revisions) responses to open questions on financials.	1.20
07/23/20	NAS	Review new Mundipharma diligence responses from S. Jamieson (Management Revisions).	1.70
07/23/20	NAS	Revise Mundipharma business plan model to include new product, category, market, and region-level metrics.	2.90
07/23/20	NAS	Map different product classifications used by Mundipharma across data sources to have common methodology.	1.60
07/23/20	NAS	Update methodology notes and assumptions used in Mundipharma business plan model.	0.90
07/23/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/23/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review and redact documents in response to diligence request for Project Catalyst.	1.70
07/23/20	ADD	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.90
07/23/20	ADD	Virtual working session with A. DePalma and K.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty (both AlixPartners) re: VDR activity.	
07/23/20	KM	Document edits and reporting re: RT org structure for Catalyst VDR.	0.70
07/23/20	KM	VDR management re: project Catalyst.	0.50
07/23/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review and redact documents in response to diligence request for Project Catalyst.	1.70
07/23/20	KM	Analysis re: inventory transition re: project Catalyst.	0.50
07/23/20	KM	Coordination of diligence visit re: project Catalyst.	0.80
07/23/20	KM	Analysis re: environmental diligence for Catalyst.	1.20
07/23/20	KM	Attend Advisors call with D. Lundie, R. Aleali, K. McCarthy (all Purdue), R. Schnitzler (PJT), K. McCafferty, J. DelConte (both AlixPartners), M. Gibson, and A. Gallogly (both Skadden) re: Project Catalyst transaction documents.	0.50
07/23/20	KM	Analysis re: excluded liabilities in transaction for project Catalyst.	0.10
07/23/20	KM	Call with A. DePalma, K. McCafferty (both AlixPartners), R. Schnitzler, J. Wang, I. Mian (all PJT), D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, and K. McCarthy (all Purdue) re: Project Catalyst VDR and diligence tracker.	0.90
07/23/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, W. DiNicola, D. Fogel (all Purdue), A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/23/20	JD	Participate in Purdue board meeting.	1.60
07/23/20	JD	Call with M. Huebner (Davis Polk) re: reporter inquiry.	0.20
07/23/20	JD	Create analysis of professional fees to send to Davis Polk and management re: reporter inquiry.	0.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/23/20	JD	Attend Advisors call with D. Lundie, R. Aleali, K. McCarthy (all Purdue), R. Schnitzler (PJT), K. McCafferty, J. DelConte (both AlixPartners), M. Gibson, and A. Gallogly (both Skadden) re: Project Catalyst transaction documents.	0.50
07/23/20	JD	Call with M. Kesselman (Purdue) re: meeting schedules.	0.20
07/23/20	JD	Call with R. Aleali (Purdue) re: court follow up.	0.20
07/23/20	JD	Review analysis of professional fees post-petition from the company.	0.40
07/23/20	JD	Update latest strategic questions memo and send out update to Purdue management.	0.80
07/23/20	JD	Review and edit latest UCC presentation and send around to internal group for review prior to prep call tomorrow.	0.70
07/23/20	KM	Analysis re: RT org structure for Catalyst VDR.	0.30
07/23/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: VDR activity.	0.70
07/23/20	KM	Update VDR tracking re: project Catalyst.	1.10
07/24/20	KM	Communicate virtual site visit plan re: project Catalyst.	0.40
07/24/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/24/20	KM	Prepare guidelines for virtual site visit re: project Catalyst.	1.40
07/24/20	KM	Design virtual site visit proposal re: project Catalyst.	0.60
07/24/20	JD	Call with C. Landau, M. Kesselman, J. Lowne (Purdue), M. Huebner, E. Vonnegut, C. Robertson (Davis Polk), J. O'Connell, J. Turner (both PJT) re: UCC meeting prep.	1.30
07/24/20	JD	Correspondence with PJT and management re: insurance	0.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		liability post-petition per UCC diligence request.	
07/24/20	JD	Correspondence with PJT and management re: strategic issues memo.	0.30
07/24/20	JD	Prepare for and attend call with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), R. Schnitzler, J. Turner (both PJT), J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.60
07/24/20	KM	Planning re: project Catalyst.	0.20
07/24/20	KM	Update VDR tracker re: project Catalyst.	0.80
07/24/20	KM	Meeting with D. Lundie, J. Lowne, K. McCarthy, R. Aleali (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden) re: project Catalyst catch-up.	1.10
07/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: VDR updates.	0.30
07/24/20	KM	Call with R. Schnitzler (PJT) re: edits to project Catalyst presentation to the Board.	0.20
07/24/20	KM	Call with M. Atkinson (Province), L. Szlezinger, K. Sheridan (both Jefferies), R. Schnitzler, J. Turner (both PJT), J. DelConte, K. McCafferty (both AlixPartners) re: Project Catalyst update.	0.50
07/24/20	KM	Meeting with R. Shamblen (Purdue), Alcaliber diligence team re: diligence interview.	1.00
07/24/20	KM	Meeting with D. Lundie, J. Lowne, K. McCarthy, R. Aleali (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly, R. Schlossberg (all Skadden) re: project Catalyst catch-up.	1.00
07/24/20	KM	Analysis re: revised volume forecast.	0.70
07/24/20	ADD	Virtual working session with A. DePalma and K.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		McCafferty (both AlixPartners) re: VDR updates.	
07/24/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau, D. Fogel, W. DiNicola (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	1.00
07/24/20	NAS	Call with M. Princen (Purdue), G. Koch, N. Simon (both AlixPartners), and other diligence advisors re: Mundipharma diligence.	0.90
07/24/20	NAS	Discussion with G. Koch, N. Simon (both AlixPartners) to share takeaways from call with Mundipharma CEO and discuss next steps.	0.60
07/24/20	NAS	Update notes and assumptions pages in revised Mundipharma business plan model.	0.90
07/24/20	NAS	Review new Invokana/Vokanamet market sizing model provided by Mundipharma.	0.90
07/24/20	NAS	Refine product classifications in Mundipharma business plan model and request further detail from company.	0.60
07/24/20	GJK	Review of Europe business plan based on discussion with Mundipharma CEO including potential refocusing of product categories.	2.00
07/24/20	GJK	Plan and coordinate Mundipharma diligence re: report and model updates, including emails from Huron on timing.	2.50
07/24/20	GJK	Discussion with G. Koch and N. Simon (both AlixPartners) to share takeaways from call with Mundipharma CEO and discuss next steps.	0.60
07/24/20	GJK	Call with M. Princen (Purdue), G. Koch, N. Simon (both AlixPartners), and other diligence advisors re: Mundipharma diligence.	0.90
07/24/20	SJC	Continue to review and redact documents from P drive in preparation for processing an upload to data room.	4.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/24/20	SJC	Review and redact documents from P drive in preparation for processing an upload to data room.	4.00
07/25/20	LJD	Review and comment on UCC deck.	1.10
07/25/20	JD	Correspondence with management, PJT and Davis Polk re: ability to share the UCC deck with all committee members.	0.50
07/25/20	JD	Correspondence with management, PJT and Davis Polk re: edits to the UCC deck for Monday.	0.70
07/27/20	JD	Call with J. O'Connell, J. Turner (both PJT), J. DelConte, H. Bhattal, L. Donahue (both AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) RE: board strategic issue questions.	0.70
07/27/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.90
07/27/20	KM	Create and circulate trackers to all bidders re: project Catalyst.	0.80
07/27/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne, D. McGuire, K. McCarthy, R. Aleali (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst supply agreement discussion.	1.60
07/27/20	KM	Coordinate interested party diligence visits re: project Catalyst.	0.60
07/27/20	KM	Structure response re: project Catalyst diligence questions.	0.40
07/27/20	KM	Review and establish virtual site visit guidelines re: project Catalyst.	0.90
07/27/20	KM	Design virtual site visit platform re: project Catalyst.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/27/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: APR redactions.	0.80
07/27/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst supply agreements management.	0.30
07/27/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.80
07/27/20	KM	Update VDR re: project Catalyst.	0.10
07/27/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review outstanding diligence request redact documents in response to diligence request for Project Catalyst.	1.10
07/27/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst operations and supply chain diligence.	0.80
07/27/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst supply agreements management.	0.80
07/27/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst supply agreements management.	0.30
07/27/20	ADD	Compile bank statements provided by Purdue's accounting service provider TXP for Purdue's accounting team review.	1.50
07/27/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review outstanding diligence request redact documents in response to	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		diligence request for Project Catalyst.	
07/27/20	LJD	Prepare for and attend call with M. Kesselman and M Heubner (both Purdue) re: board questions and issues	0.40
07/27/20	LJD	Call with J. O'Connell, J. Turner (both PJT), J. DelConte, H. Bhattal, L. Donahue (both AlixPartners), M. Huebner, E. Vonnegut, C. Robertson (all Davis Polk), M. Kesselman, R. Aleali (both Purdue) RE: board strategic issue questions.	0.70
07/27/20	GJK	Call with N. Simon (AlixPartners) re: findings from research into Mundipharma P&L structure.	1.00
07/27/20	GJK	Working capital analysis and prep for call with Mundipharma Treasurer.	2.50
07/27/20	GJK	Review of updates Mundipharma Malta 2.0 model.	0.80
07/27/20	GJK	Comparison and analysis of updates to Malta Model 2.0 and original EY VDD.	2.20
07/27/20	NAS	Review new Mundipharma diligence materials provided by management/Huron.	0.70
07/27/20	NAS	Further research into Mundipharma income statement items to ensure all appropriate lines are incorporated in model.	2.90
07/27/20	NAS	Correspondence with other Mundipharma diligence advisors re: latest requests for company.	0.50
07/27/20	NAS	Call with G. Koch (AlixPartners) re: findings from research into Mundipharma P&L structure.	1.00
07/28/20	NAS	Prepare for diligence call with D. Jefferies (Mundipharma Treasurer).	0.30
07/28/20	NAS	Calls with G. Koch (AlixPartners) to discuss takeaways from D. Jefferies (Mundipharma) meeting and review current draft of business plan model.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/28/20	NAS	Arrange source data in Mundipharma business plan model to run more efficiently.	1.90
07/28/20	NAS	Build product category standalone P&Ls in revised Mundipharma business plan model.	2.80
07/28/20	GJK	Review and walkthrough of updates to Malta 2.0 model and inclusions into EBITDA including EY VDD, work ok tie into potential cash flows.	2.00
07/28/20	GJK	Review of transaction perimeter and settlement framework language as it relates to Mundipharma joint ventures.	0.80
07/28/20	GJK	Coordinate work stream activities, including exchanges with Province and FTI on state of diligence and next steps/priority open items.	2.60
07/28/20	GJK	Calls with N. Simon (AlixPartners) to discuss takeaways from D. Jefferies (Mundipharma) meeting and review current draft of business plan model.	1.00
07/28/20	GJK	Call with J Turner (PJT) re: call with Province and FTI on current state of Mundipharma diligence responses.	0.20
07/28/20	ADD	Compile additional historical bank statements provided by Purdue's accounting service provider TXP for Purdue's accounting team review and transfer files to file transfer program.	1.40
07/28/20	ADD	Meeting with D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), K. McCafferty, and A. DePalma (both AlixPartners) re: project Catalyst VDR.	0.50
07/28/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update.	0.20
07/28/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	
07/28/20	KM	Analysis and VDR updates re: project Catalyst.	1.10
07/28/20	KM	Meeting with D. Fogel, R. Shamblen, J. Doyle, W. DiNicola, K. McCarthy (all Purdue), R. Schnitzler, J. Wang, I. Mian (all PJT), and A. DePalma (AlixPartners) re: project Catalyst VDR.	0.50
07/28/20	KM	Prepare for and attend meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), and A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	0.50
07/28/20	KM	Analysis and preparation re: EHS and diligence site visits for project Catalyst.	1.80
07/28/20	KM	Meeting with R. Schnitzler (PJT) diligence team re: Catalyst offer feedback.	0.30
07/28/20	KM	VDR updates re: project Catalyst.	0.40
07/28/20	KM	Analysis re: site visit strategy for Catalyst.	1.00
07/28/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	0.50
07/28/20	KM	Call with A. DePalma and K. McCafferty (AlixPartners) re: Project Catalyst due diligence status update.	0.20
07/28/20	KM	Call with D. Lundie (Purdue) re: project Catalyst legal progress.	0.40
07/28/20	KM	Review Supply agreement re: project Catalyst.	0.70
07/29/20	KM	Review long form documents re: project Catalyst.	0.80
07/29/20	KM	Create site visit documents re: project Catalyst.	1.50
07/29/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (Rhodes),	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	
07/29/20	KM	Prepare response re: proposal.	0.50
07/29/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst daily updates.	1.00
07/29/20	KM	Analysis and review of site surveys re: project Catalyst.	0.70
07/29/20	KM	Call with D. Lundie (Purdue), R. Schnitzler (PJT) re: response for project Catalyst.	0.30
07/29/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, A. Gallogly (both Skadden) re: project Catalyst Supply Agreement.	1.00
07/29/20	KM	Update virtual site documentation re: interested party specific requests.	0.40
07/29/20	KM	Update diligence requests and tracker re: project Catalyst.	0.30
07/29/20	KM	Upload and edit site visit documents re: project Catalyst.	2.30
07/29/20	JD	Follow up correspondence with management, PJT and Davis Polk RE: business development deal.	0.50
07/29/20	ADD	Prepare and upload documentation to AlixPartners eDiscovery team for upload to Relativity.	0.80
07/29/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.50
07/29/20	GJK	Prepare for call with Management Revisions and walkthrough of open items to be addressed by S. Jamieson (Management Revisions).	2.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/29/20	GJK	Call with N. Simon (AlixPartners) to discuss current version of Mundipharma business plan model and next steps.	0.40
07/29/20	GJK	Review of VDD relative to Malta 2.0 model categories.	2.60
07/29/20	GJK	Review of Consumer Health VDD to compare against implied Consumer Health categorization in Malta model.	2.60
07/29/20	NAS	Revise Mundipharma business plan model to include category and business line-level standalone scenarios.	2.20
07/29/20	NAS	Build check function for category standalone scenarios in Mundipharma business plan model.	1.10
07/29/20	NAS	Call with G. Koch (AlixPartners) to discuss current version of Mundipharma business plan model and next steps.	0.40
07/29/20	NAS	Build business line-level standalone scenario in Mundipharma business plan model.	1.20
07/29/20	NAS	Refine allocation methodology in Mundipharma business plan model for standalone scenarios.	2.10
07/29/20	LJD	Call with M. Kesselman (Purdue) re: Board Meeting.	0.30
07/29/20	LJD	Call with K Buckfire (board member) and M. Kesselman (Purdue) re: board meeting and outstanding issues.	0.30
07/29/20	LJD	Review draft board deck and comment.	0.70
07/30/20	LJD	Prepare for and attend Purdue board meeting (partial participation).	3.50
07/30/20	LJD	Review and comment on chart for board strategic questions.	0.40
07/30/20	NAS	Review of revised standalone cases in Mundipharma business plan model with G. Koch (AlixPartners).	0.60
07/30/20	NAS	Consolidate and review notes/follow-ups from meetings with S. Jamieson (Management Revisions) and other Mundipharma diligence advisors (FTI, Province).	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/30/20	NAS	Compare EY Consumer Health VDD report to latest model and revise allocation methodologies as appropriate.	2.90
07/30/20	NAS	Call with G. Koch (AlixPartners) to review takeaways from diligence meeting with S. Jamieson (Management Revisions).	0.50
07/30/20	GJK	Walkthrough of updates to Malta 2.0 model and outline comparative approaches to bridging to previous base case.	2.00
07/30/20	GJK	Call with N. Simon (AlixPartners) to review takeaways from diligence meeting with S. Jamieson (Management Revisions).	0.50
07/30/20	GJK	Review of revised standalone cases in Mundipharma business plan model with N. Simon (AlixPartners).	0.60
07/30/20	GJK	Plan and coordinate next steps in diligence process based on week's calls and proposed timeline for release of new information.	2.40
07/30/20	JD	Correspondence with management RE: business development deal follow ups.	0.20
07/30/20	JD	Call with M. Huebner (Davis Polk) RE: UCC meeting recap.	0.10
07/30/20	JD	Review board material pre-reads in advance of board call.	0.80
07/30/20	JD	Participate in final session of PPI Board meeting.	1.00
07/30/20	JD	Review final board strategic issues draft from PJT.	0.70
07/30/20	ADD	Meeting with A. Nadeau, (Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst operations and virtual site visit preparations.	1.80
07/30/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/30/20	JD	Participate in PPI Board meeting.	4.70
07/30/20	KM	Coordinate and communicate re: project Catalyst diligence.	0.60
07/30/20	KM	Call with R. Schnitzler (PJT) re: project Catalyst coordination for interested party diligence.	0.10
07/30/20	KM	Review of additional site visit photos re: project Catalyst.	0.70
07/30/20	KM	Call with A. Nadeau (Purdue) re: virtual site visit for project Catalyst.	1.10
07/30/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst status update meeting.	0.50
07/30/20	KM	Update environmental diligence requests re: project Catalyst.	0.90
07/30/20	KM	Create virtual visit overview and tour route map re: project Catalyst.	0.80
07/30/20	KM	Meeting with A. Nadeau (Purdue), A. DePalma, and K. McCafferty (both AlixPartners) re: Catalyst operations and virtual site visit preparations.	1.80
07/30/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle, J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, and A. Gallogly (both Skadden) re: project Catalyst Supply Agreement.	1.50
07/30/20	KM	Participate in Purdue BOD meeting (partial participation).	0.40
07/30/20	KM	Update diligence progress re: project Catalyst.	0.60
07/31/20	KM	Editing re: project Catalyst site tour agenda and plan.	0.50
07/31/20	KM	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), and A. DePalma (AlixPartners) re: Catalyst operations and supply chain diligence.	1.50
07/31/20	KM	Meeting with D. Lundie, R. Shamblen, D. Fogel, J. Doyle,	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
		J. Lowne (all Purdue), R. Schnitzler (PJT), M. Gibson, and A. Gallogly (both Skadden) re: project Catalyst daily updates.	
07/31/20	KM	Analysis and presentation prep re: virtual site visit for project Catalyst.	1.80
07/31/20	KM	Create presentation documents re: virtual site visit for project Catalyst.	1.40
07/31/20	KM	Coordinate VDR updates with Rhodes Operations and Finance re: project Catalyst.	0.80
07/31/20	KM	Call with A. Soma (Purdue) and A. DePalma (AlixPartners) re: manufacturing presentation materials for virtual site tour.	0.70
07/31/20	ADD	Call with A. Soma (Purdue) and K. McCafferty (AlixPartners) re: manufacturing presentation materials for virtual site tour.	0.70
07/31/20	JD	Review docket for recently filed fee apps to update latest professional fee tracker for Davis Polk.	0.60
07/31/20	JD	Review materials created and provided to the UCC RE: opioid scenarios.	1.20
07/31/20	JD	Call with J. DelConte, G. Koch, N. Simon (AlixPartners), J. Turner (PJT), R. Schnitzler (PJT), J. Arsic (PJT), and I. Mian (PJT) to provide update on information received during 7/30 discussion with FTI and Province.	0.50
07/31/20	GJK	Call with N. Simon (AlixPartners) to review Consumer Health figures in latest Mundipharma business plan model relative to EY VDD.	0.40
07/31/20	GJK	Plan for updates to Mundipharma review deck.	1.50
07/31/20	GJK	Review of interim Mundipharma report and back up detail related to other Financial Advisor challenges with developing reports.	1.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Date	Consultant	Description of Services	Hours
07/31/20	GJK	Call with J. DelConte, G. Koch, N. Simon (AlixPartners), J. Turner (PJT), R. Schnitzler (PJT), J. Arsic (PJT), and I. Mian (PJT) to provide update on information received during 7/30 discussion with FTI and Province.	0.50
07/31/20	NAS	Coordination with other Mundipharma diligence advisors re: current status of diligence process.	0.50
07/31/20	NAS	Call with G. Koch (AlixPartners) to review Consumer Health figures in latest Mundipharma business plan model relative to EY VDD.	0.40
07/31/20	NAS	Call with J. DelConte, G. Koch, N. Simon (AlixPartners), J. Turner (PJT), R. Schnitzler (PJT), J. Arsic (PJT), and I. Mian (PJT) to provide update on information received during 7/30 discussion with FTI and Province.	0.50
07/31/20	NAS	Compare latest draft of Mundipharma business plan model to version used in prior iteration of report.	0.50
07/31/20	LJD	Call with M Kesselman (Purdue) re: board meeting.	0.40
Total			627.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Business Analysis & Operations
Client/Matter # 012589.00106

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	39.20	515.00	20,188.00
Sam K Lemack	8.70	515.00	4,480.50
Nate A Simon	113.20	515.00	58,298.00
Sam J Canniff	8.00	645.00	5,160.00
Isabel Arana de Uriarte	2.20	690.00	1,518.00
Ryan D Sublett	0.40	735.00	294.00
Gabe J Koch	138.20	840.00	116,088.00
HS Bhattal	0.50	840.00	420.00
Jesse DelConte	118.70	950.00	112,765.00
Kevin M McCafferty	177.50	950.00	168,625.00
Lisa Donahue	21.20	1,195.00	25,334.00
Total Hours & Fees	627.80		513,170.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: POR Development
Client/Matter # 012589.00107

Date	Consultant	Description of Services	Hours
07/22/20	SKL	Participate in Liquidation analysis meeting with J. DelConte, HS Bhattal and S. Lemack (all AlixPartners).	0.50
07/22/20	JD	Participate in Liquidation analysis meeting with J. DelConte, HS Bhattal and S. Lemack (all AlixPartners).	0.50
07/22/20	ADD	Compile materials for liquidation analysis and review representative examples.	2.30
07/22/20	HSB	Participate in Liquidation analysis meeting with J. DelConte, HS Bhattal and S. Lemack (all AlixPartners).	0.50
Total			3.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: POR Development
Client/Matter # 012589.00107

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	2.30	515.00	1,184.50
Sam K Lemack	0.50	515.00	257.50
HS Bhattal	0.50	840.00	420.00
Jesse DelConte	0.50	950.00	475.00
Total Hours & Fees	3.80		2,337.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
07/01/20	BJF	Match vendor names for claims reconciliation.	2.40
07/01/20	BJF	Match vendors for claims resolution.	1.90
07/01/20	MBB	Review claims database to determine duplicate claims and matched.	2.70
07/01/20	MBB	Review claims database and matched duplicate filings.	2.40
07/01/20	SKL	Review and reconcile the claims summary report and continued matching updates accordingly.	0.90
07/02/20	MBB	Review claims database to determine duplicate claims and matched.	1.80
07/02/20	MBB	Search filed claims for duplicate filings.	2.60
07/02/20	BJF	Research third party confidentiality for due diligence request.	1.10
07/06/20	MBB	Search filed claims for duplicate filings.	2.90
07/06/20	MBB	Review claims database to determine duplicate claims and matched.	2.90
07/06/20	MBB	Review claims database to determine duplicate claims and assigned match numbers to new claims.	2.70
07/07/20	MBB	Search filed claims for duplicate filings.	2.20
07/07/20	MBB	Review claims database to determine duplicate claims and assigned match numbers to new claims.	2.90
07/07/20	MBB	Review claims database to determine duplicate claims and matched.	2.70
07/07/20	BJF	Match vendor names for claims reconciliation.	2.60
07/08/20	BJF	Match vendor names for claims reconciliation.	2.90
07/08/20	BJF	Match vendors for claims resolution.	2.80
07/08/20	MBB	Search filed claims for duplicate filings.	2.70
07/08/20	MBB	Review claims database to determine duplicate claims and	2.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Claims Process
Client/Matter # 012589.00109

Date	Consultant	Description of Services	Hours
		assigned match numbers to new claims.	
07/08/20	MBB	Review claims database to determine duplicate claims and matched.	2.60
07/09/20	MBB	Search filed claims for duplicate filings.	2.40
07/10/20	BJF	Match vendor names for claims reconciliation.	1.30
07/13/20	BJF	Match vendor names for claims reconciliation.	2.90
07/13/20	BJF	Match vendors for claims resolution.	2.40
07/13/20	BJF	Continue to match vendor names for claims reconciliation.	1.70
07/15/20	JD	Review claims estimation presentation.	0.40
Total			59.70

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Claims Process
Client/Matter # 012589.00109

Fee Recap:

Consultant	Hours	Rate	Amount
Mary B Betik	36.40	315.00	11,466.00
Barbara J Ferguson	22.00	315.00	6,930.00
Sam K Lemack	0.90	515.00	463.50
Jesse DelConte	0.40	950.00	380.00
Total Hours & Fees	59.70		19,239.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
07/01/20	KG	Load third party production into Relativity including image documents, update/overlay data and index for search/retrieval.	0.40
07/01/20	KG	Update SPOT tracking documentation and generate document listing.	0.40
07/01/20	KG	Process data for loading including export and import into Relativity.	0.40
07/01/20	ADD	Compile materials provided in response to Project Catalyst diligence request and submit materials for legal and business approval,	2.40
07/01/20	ADD	Compile and review responses to Project Catalyst diligence requests and upload files to the data room.	1.90
07/01/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst due diligence status update and compilation of diligence responses, and upload materials to the VDR.	2.00
07/06/20	ADD	Download accounts payable data to update liabilities subject to compromise calculation.	0.50
07/06/20	ADD	Compile documents and request approval to upload files to the Project Catalyst VDR.	1.60
07/07/20	ADD	Review and compile materials produced in response to diligence requests for Project Catalyst	2.30
07/07/20	KG	Process data for loading including export and import into Relativity.	0.30
07/07/20	KG	Load image documents and update/overlay data and index for search/retrieval.	0.30
07/07/20	KG	Update SPOT tracking documentation including import third party production and update/overlay data and index for search/retrieval.	0.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
07/08/20	ADD	Compile materials and request approval to upload files to the Project Catalyst data room.	2.60
07/09/20	ADD	Review and compile materials produced in response to diligence requests for debtor entities.	1.80
07/10/20	ADD	Compile materials and request approval to upload files to the Project Catalyst data room.	2.10
07/13/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst VDR and diligence progress.	0.40
07/13/20	ADD	Review and compile debtor entity employee title history for upload to the data room.	1.90
07/13/20	ADD	Call with A. DePalma and K. McCafferty (both AlixPartners), re: Project Catalyst VDR and diligence progress.	0.40
07/14/20	ADD	Download and compile Rhodes Tech agreements from the contract database with entities (A through L) for review and analysis.	3.30
07/14/20	ADD	Download and compile Rhodes Tech agreements from the contract database with entities (J through Z) for review and analysis.	3.10
07/16/20	ADD	Compile Rhodes contracts in preparation for Project Catalyst diligence requests.	2.60
07/20/20	ADD	Compile and format items submitted in response to diligence requests for upload to the Project Catalyst data room.	2.70
07/21/20	ADD	Compile and upload Project catalyst diligence materials for external legal review.	1.40
07/22/20	ADD	Upload documents submitted in response to diligence requests and request approval from external legal counsel.	1.80

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
07/23/20	ADD	Compile files submitted in response to diligence requests for Project Catalyst.	1.30
07/23/20	ADD	Request approval to release files to the Project Catalyst data room.	0.90
07/24/20	ADD	Request approval to provide documents to interested parties in response to Project Catalyst diligence requests.	0.40
07/24/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR.	0.60
07/24/20	ADD	Compile list of material agreements to request consent to disclose for Project Catalyst.	1.90
07/24/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR.	0.60
07/24/20	KG	Export and re-image documents in LAW database including export and email correspondence to replace corrupt images with new ones.	0.70
07/24/20	KG	Stage and load data into Relativity including perform quality control review of loaded data, update/overlay data and index for search/retrieval and create file listing of new documents.	1.20
07/27/20	ADD	Compile list of third-parties to request consent to disclose relationship details including agreements.	1.50
07/27/20	ADD	Review and redact documents in preparation to produce in response to Project Catalyst diligence request.	1.10
07/28/20	ADD	Update Project Catalyst data room, removing users that no longer require access.	0.40
07/28/20	ADD	Update with additional data elements the list of third-parties used by Rhodes to request consent to disclose relationship details including agreements.	1.10

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Special Projects
Client/Matter # 012589.00110

Date	Consultant	Description of Services	Hours
07/29/20	ADD	Prepare files submitted in response to Project Catalyst diligence request and upload files to data room.	2.20
07/29/20	KG	Stage and process data including perform quality control review of processed data.	0.60
07/29/20	KG	Export and import data into Relativity including perform quality control review of loaded data, update/overlay data and index for search/retrieval, and update SPOT tracking documentation.	1.00
07/31/20	ADD	Review outstanding materials responsive to project catalyst diligence request and prepare documents for upload to data room.	0.30
07/31/20	ADD	Meeting with R. Shamblen, A. Soma, A. Nadeau (all Purdue), A. DePalma and K. McCafferty (AlixPartners) re: Catalyst status update meeting.	1.50
07/31/20	ADD	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR.	1.00
07/31/20	ADD	Request approval to upload files compiled in response to diligence request to Project Catalyst data room.	0.70
07/31/20	KM	Virtual working session with A. DePalma and K. McCafferty (both AlixPartners) re: Review approved documents and upload materials to Project Catalyst VDR.	1.00
Total			56.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Special Projects
Client/Matter # 012589.00110

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	49.70	515.00	25,595.50
Kristina Galbraith	5.60	645.00	3,612.00
Kevin M McCafferty	1.60	950.00	1,520.00
Total Hours & Fees	56.90		30,727.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
07/01/20	TB	Prepare ninth monthly fee statement May 2020 and exhibits.	1.80
07/02/20	TB	Update ninth monthly fee statement for May 2020.	0.60
07/02/20	JD	Review final version of the May fee statement to be filed with the court.	0.30
07/06/20	LJD	Review and comment on 9th monthly fee statement.	0.40
07/06/20	MSM	Prepare professional fees for June 2020 fee statement.	2.50
07/06/20	MSM	Continue to prepare professional fees for June 2020 fee statement.	3.00
07/07/20	MSM	Prepare professional fees for June 2020 fee statement.	1.50
07/08/20	TB	Prepare workbook for the second interim.	1.90
07/09/20	TB	Prepare second interim fee application and exhibits.	3.20
07/09/20	TB	Continue to prepare second interim fee application and exhibits.	1.40
07/09/20	MSM	Prepare professional fees for June 2020 fee statement.	2.50
07/10/20	MSM	Prepare professional fees for June 2020 fee statement.	2.80
07/10/20	JD	Review and provide comments on the 2nd interim fee application draft.	1.00
07/13/20	TB	Update fee and expense status chart. Update the second interim fee application.	0.40
07/13/20	MSM	Prepare professional fees for June 2020 fee statement.	1.70
07/14/20	JD	Review final second interim fee application.	0.50
07/16/20	MSM	Prepare professional fees for June 2020 fee statement.	3.80
07/17/20	MSM	Prepare professional fees for June 2020 fee statement.	3.50
07/17/20	MSM	Continue to prepare professional fees for June 2020 fee statement.	3.10
07/17/20	MSM	Further preparation of professional fees for June 2020 fee	2.40

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Date	Consultant	Description of Services	Hours
		statement.	
07/18/20	MSM	Prepare professional fees for June 2020 fee statement.	2.80
07/19/20	MSM	Prepare professional fees for June 2020 fee statement.	2.80
07/19/20	MSM	Continue to prepare professional fees for June 2020 fee statement.	1.80
07/23/20	MSM	Prepare professional fees for July 2020 fee statement.	2.50
07/24/20	MSM	Prepare professional fees for July 2020 fee statement.	3.40
07/27/20	MSM	Prepare professional fees for July 2020 fee statement.	1.80
07/28/20	MSM	Prepare professional fees for July 2020 fee statement.	2.50
07/31/20	MSM	Prepare professional fees for July 2020 fee statement.	1.50
07/31/20	JD	Begin initial review of June fee statement for filing with the court.	1.80
07/31/20	JD	Finalize review of June fee statement.	2.30
Total			61.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Fee Statements and Fee Applications
Client/Matter # 012589.00113

Fee Recap:

Consultant	Hours	Rate	Amount
Melanie McCabe	45.90	415.00	19,048.50
Tammy Brewer	9.30	450.00	4,185.00
Jesse DelConte	5.90	950.00	5,605.00
Lisa Donahue	0.40	1,195.00	478.00
Total Hours & Fees	61.50		29,316.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Court Hearings
Client/Matter # 012589.00114

Date	Consultant	Description of Services	Hours
07/23/20	JD	Participate in Purdue court hearing.	3.20
Total			3.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Court Hearings
Client/Matter # 012589.00114

Fee Recap:

Consultant	Hours	Rate	Amount
Jesse DelConte	3.20	950.00	3,040.00
Total Hours & Fees	3.20		3,040.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/01/20	RC	Call with S. Canniff, R. Collura (both AlixPartners) to review and discuss responses to tax diligence requests.	1.00
07/01/20	RC	Call with S. Canniff, R. Collura, and A. DePalma (all AlixPartners) to review information available in SAP and discuss responses to the UCC's tax diligence requests.	0.50
07/01/20	RC	Review tax distribution support documentation gathered in response to requests from the UCC.	0.90
07/01/20	RC	Review and respond to requests from Davis Polk about tax distributions.	0.40
07/01/20	SJC	Meeting with A. DePalma and S. Canniff (both AlixPartners) re: diligence requests.	0.50
07/01/20	SJC	Call with S. Canniff, R. Collura, and A. DePalma (all AlixPartners) to review information available in SAP and discuss responses to the UCC's tax diligence requests.	0.50
07/01/20	SJC	Call with S. Canniff, R. Collura (both AlixPartners) to review and discuss responses to tax diligence requests.	1.00
07/01/20	SJC	Pulling support for 2014 tax distributions for data room.	2.50
07/01/20	SJC	Pulling support for 2015 tax distributions for data room.	2.00
07/01/20	SJC	Pulling support for 2009 tax distributions for data room.	1.50
07/01/20	ADD	Meeting with A. DePalma and S. Canniff (both AlixPartners) re: diligence requests.	0.50
07/01/20	ADD	Call with S. Canniff, R. Collura, and A. DePalma (all AlixPartners) to review information available in SAP and discuss responses to the UCC's tax diligence requests.	0.50
07/02/20	SJC	Pulling support for 2013 tax distributions for data room.	2.00
07/02/20	SJC	Pulling support for 2011 tax distributions for data room.	1.00
07/02/20	SJC	Review and analysis of 2014 tax distribution.	1.00
07/02/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: UCC	0.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		filings and information requests.	
07/02/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: UCC filings and information requests.	0.20
07/02/20	RC	Call with M. Clarens (Davis Polk) to discuss information related to the tax distributions.	0.30
07/02/20	RC	Review and respond to Davis Polk re: information related to tax distribution calculations.	0.40
07/06/20	RC	Review documentation related the tax distributions requested by the UCC.	1.20
07/06/20	SJC	Review and analysis of 2014 tax distribution.	3.00
07/06/20	SJC	Continue review and analysis of 2014 tax distribution.	2.00
07/07/20	SJC	Review and analysis of 2014 tax distribution.	1.00
07/07/20	SJC	Review and analysis of 2012 tax distribution.	3.00
07/07/20	FOS	Compose email to A. DePalma (AlixPartners) re: Information request from Province.	0.20
07/07/20	RC	Review and comment on responses to requests from the UCC re: SAP information.	0.20
07/07/20	RC	Review documentation related to tax distributions in response to requests from the UCC.	0.90
07/07/20	RC	Review status of outstanding requests from the UCC.	0.20
07/08/20	RC	Review documents gathered in response to requests from the UCC.	0.20
07/08/20	RC	Review support documentation gathered in response to the UCC's requests for tax distribution information.	0.80
07/08/20	RC	Review and respond to diligence questions from Davis Polk re: Rhodes information.	0.20
07/08/20	SJC	Review and analysis of 2012 tax distribution.	1.00
07/08/20	SJC	Review and analysis of 2014 tax distribution.	3.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/09/20	SJC	Review and analysis of 2010 tax distribution.	3.00
07/09/20	SJC	Continue review and analysis of 2010 tax distribution.	2.00
07/09/20	RC	Review and provide comments re: tax distributions support documentation.	1.40
07/09/20	RC	Review and respond to questions from Davis Polk re: tax information requests.	0.10
07/09/20	RC	Coordinate with team and responding to additional requests made by the UCC's advisors.	0.10
07/10/20	RC	Review tax information gathered in response to requests from the UCC's advisors.	0.60
07/10/20	RC	Review and comment on responses to requests from the UCC's advisors related to tax withholding information.	0.30
07/10/20	RC	Review and comment on tax distribution support documentation.	0.60
07/10/20	SJC	Review and analysis of 2012 tax distribution.	1.00
07/10/20	SJC	Call A. DePalma, S. Canniff, and M. Hartley (all AlixPartners) discussion of UCC request for real estate taxes and payroll withholding taxes.	0.50
07/10/20	SJC	Pulling support for 2014 tax distributions for data room.	2.00
07/10/20	SJC	Pulling support for 2012 tax distributions for data room.	1.50
07/10/20	MH	Call A. DePalma, S. Canniff, and M. Hartley (all AlixPartners) discussion of UCC request for real estate taxes and payroll withholding taxes.	0.50
07/10/20	MH	Finalize report info for creditors	1.00
07/10/20	ADD	Call A. DePalma, S. Canniff, and M. Hartley (all AlixPartners) discussion of UCC request for real estate taxes and payroll withholding taxes.	0.50
07/10/20	ADD	Compile investigation support materials in response to	1.90

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		creditor diligence requests.	
07/13/20	ADD	Review of tax materials provided by TXP to identify materials produced in the data room.	1.80
07/13/20	SJC	Review and analysis of 2010 tax distribution.	3.00
07/13/20	SJC	Continue review and analysis of 2010 tax distribution.	3.00
07/13/20	RC	Review tax distribution information and respond to requests from Davis Polk.	0.40
07/14/20	RC	Review and comment on tax distribution support documentation.	1.20
07/14/20	SJC	Review and analysis of 2010 tax distribution.	4.00
07/14/20	SJC	Review and analysis of 2008 tax distribution.	2.50
07/15/20	SJC	Review and analysis of 2010 tax distribution.	2.00
07/15/20	SJC	Review and analysis of 2008 tax distribution.	2.00
07/16/20	SJC	Review and analysis of 2010 tax distribution.	3.00
07/17/20	SJC	Review and analysis of 2008 tax distribution.	3.00
07/17/20	SJC	Continue Review and analysis of 2008 tax distribution.	1.00
07/19/20	RC	Review and respond to email from FTI re: the intercompany and non-cash transfers of value report.	0.10
07/20/20	RC	Review documentation related to tax distribution support.	0.60
07/20/20	SJC	Pulling support for 2010 tax distributions for data room.	1.50
07/20/20	SJC	Pulling support for 2008 tax distributions for data room.	1.00
07/20/20	SJC	Review and analysis of 2010 tax distribution.	2.50
07/20/20	SJC	Review and analysis of 2008 tax distribution.	2.00
07/20/20	MFR	Call with M. Rule and F. Silva (both AlixPartners) re: follow-up questions from counsel on Report 1B.	0.70
07/20/20	MFR	Review of documents and analyses re: follow-up questions from counsel on Report 1B.	1.30

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/20/20	FOS	Call with M. Rule and F. Silva (both AlixPartners) re: follow-up questions from counsel on Report 1B.	0.70
07/20/20	FOS	Review documents re: Tax equalization payments for D. Lundie (Purdue).	0.30
07/21/20	SJC	Pulling support for 2014 ex us distributions.	3.00
07/21/20	SJC	Analyze and review support for 2014 ex us distributions.	1.50
07/22/20	SJC	Pulling support for 2014 ex us distributions.	3.00
07/22/20	SJC	Analyze and review support for 2014 ex us distributions.	3.00
07/22/20	SJC	Continue to analyze and review support for 2014 ex us distributions.	2.00
07/22/20	FOS	Compose email to M. Clarens (Davis Polk) re: D. Lundie (Purdue) secondment agreement.	0.10
07/23/20	RC	Review additional tax distribution support and research questions from the UCC.	1.20
07/23/20	RC	Call with R. Collura, A. DePalma (both AlixPartners), C. Oluwole, T. Matlock and A. Guo (all Davis Polk) re: tax distribution support and questions from the UCC.	0.40
07/23/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) re: tax diligence status.	0.40
07/23/20	RC	Review T&E information and respond to questions from Davis Polk.	0.30
07/23/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners), C. Oluwole, T. Matlock and A. Guo (all Davis Polk) re: tax distribution support and questions from the UCC.	0.40
07/23/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) re: tax diligence status.	0.40
07/24/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) to discuss additional work to perform based on diligence requests from Davis Polk.	0.50

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/24/20	RC	Review information gathered in connection with reports 1a and 1b in preparation for call with Davis Polk.	0.50
07/24/20	RC	Call with K. Wolfgang and E. Kim (both Davis Polk) to discuss additional diligence requests re: reports 1A and 1B.	0.50
07/24/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) to discuss additional work to perform based on diligence requests from Davis Polk.	0.50
07/27/20	RC	Research information related to additional questions from Davis Polk re: T&E expenses.	1.10
07/27/20	RC	Call with A. DePalma (AlixPartners) re: outstanding diligence requests and research questions from Davis Polk.	1.40
07/27/20	RC	Review and analysis of tax distribution related information in response to diligence requests.	1.30
07/27/20	RC	Review communications from Davis Polk re: tax distributions and bank statements.	0.10
07/27/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and research of questions from Davis Polk.	1.40
07/28/20	ADD	Research historical board materials to understand historical corporate actions.	2.60
07/28/20	RC	Review documents gathered in response to the UCC's diligence requests.	0.60
07/28/20	RC	Review documents related to tax distributions.	0.70
07/28/20	RC	Research information related to diligence related questions from Davis Polk.	1.00
07/28/20	RC	Review support information gathered in response to cash distributions diligence requests.	0.60

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/28/20	RC	Review tax information in response to diligence questions from Davis Polk.	0.50
07/29/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and Purdue/TXP tax distribution procedures.	1.20
07/29/20	RC	Review various partnership agreements related to diligence requests from Davis Polk.	0.90
07/29/20	RC	Draft email to Davis Polk re: responses to IAC diligence requests.	0.50
07/29/20	RC	Perform additional research and prepare email to Davis Polk re: responses to diligence requests related to the family members.	0.60
07/29/20	RC	Call with R. Collura, A. DePalma (both AlixPartners), K. Wolfgang and E. Kim (both Davis Polk) re: responses to family related diligence requests and additional follow-up.	0.50
07/29/20	RC	Review board materials in response to diligence requests from the UCC.	0.80
07/29/20	RC	Review documents related to partnership ownership structure in response to diligence questions.	1.10
07/29/20	RC	Review information related to tax distributions in response to diligence requests.	1.00
07/29/20	FOS	Review documents from client re: specific Purdue personnel.	0.20
07/29/20	NAS	Research and respond to IAC question posed by R. Collura (AlixPartners).	0.80
07/29/20	ADD	Research historical board materials to understand change in directors and offices and other corporate actions.	1.80
07/29/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and Purdue/TXP tax	1.20

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
		distribution procedures.	
07/29/20	ADD	Call with R. Collura, A. DePalma (both AlixPartners), K. Wolfgang and E. Kim (both Davis Polk) re: responses to family related diligence requests and additional follow-up.	0.50
07/30/20	ADD	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and review of AP activity.	0.70
07/30/20	ADD	Document Purdue tax distribution process at request of Davis Polk to understand process and changes over time.	2.80
07/30/20	SJC	Review and redact documents from Finance Folder(s) in preparation for processing an upload to data room.	2.50
07/30/20	FOS	Call with M. Rule (AlixPartners) re: information requests from Davis Polk.	0.10
07/30/20	MFR	Call with F. Silva (AlixPartners) re: information requests from Davis Polk.	0.10
07/30/20	RC	Review support documentation related to tax distributions and update questions for Purdue and TXP.	0.60
07/30/20	RC	Call with R. Collura and A. DePalma (both AlixPartners) re: Outstanding diligence requests and review of AP activity.	0.70
07/30/20	RC	Review documents provided Davis Polk and prepare questions re: tax distribution process.	0.50
07/30/20	RC	Review tax related documentation and update questions for Purdue and TXP.	1.30
07/30/20	RC	Review cash transfer of value report in connection with responding to diligence requests.	0.80
07/31/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding diligence requests and review of vendor payment activity.	1.00

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Date	Consultant	Description of Services	Hours
07/31/20	RC	Call with A. DePalma and R. Collura (both AlixPartners) to discuss additional outstanding tax information diligence requests.	0.80
07/31/20	RC	Call with J. DelConte and R. Collura (both AlixPartners) re: status of creditor investigation diligence.	0.20
07/31/20	RC	Review additional tax distributions support gathered in response to the UCC's requests.	1.70
07/31/20	RC	Review additional support gathered in response to the UCC's requests related to tax calculations and tax distributions.	1.20
07/31/20	RC	Review information related to tax calculations in response to requests from the UCC.	1.30
07/31/20	JD	Call with J. DelConte and R. Collura (both AlixPartners) re: status of creditor investigation diligence.	0.20
07/31/20	FOS	Prepare responsive documents re: UCC information requests.	0.50
07/31/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss additional outstanding tax information diligence requests.	0.80
07/31/20	ADD	Call with A. DePalma and R. Collura (both AlixPartners) to discuss outstanding diligence requests and review of vendor payment activity.	1.00
Total			<u>147.30</u>

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2

Re: Forensic Analysis
Client/Matter # 012589.00115

Fee Recap:

Consultant	Hours	Rate	Amount
Andrew D DePalma	19.30	515.00	9,939.50
Nate A Simon	0.80	515.00	412.00
Fernando O Silva	2.30	645.00	1,483.50
Sam J Canniff	80.50	645.00	51,922.50
Michael Hartley	1.50	840.00	1,260.00
Mark F Rule	2.30	910.00	2,093.00
Jesse DelConte	0.20	950.00	190.00
Richard Collura	40.40	1,090.00	44,036.00
Total Hours & Fees	147.30		111,336.50

Exhibit B

Alix Partners, LLP

Summary and Detailed Description of AlixPartners' Expenses

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2
Re: Expense
Client/Matter # 012589.00150

Date	Disbursement Description	Amount
06/19/20	Copy Costs (Outside Source) Gabriel Koch Print Out 230 Pages Of A Draft Diligence Report For Editing	138.35
	Total Disbursements	138.35

AlixPartners

Mr. Jon Lowne
Chief Financial Officer
Purdue Pharma L.P.
One Stamford Forum
201 Tresser Boulevard
Stamford, CT 06901-3431

Mr. James P. Doyle
Vice President & General Counsel
Rhodes Technologies
Rhodes Pharmaceuticals L.P.
498 Washington Street
Coventry, RI 02816

Invoice # 2126962-2
Re: Expense
Client/Matter # 012589.00150

Disbursement Recap:

Description	Amount
Other	138.35
Total Disbursements	138.35